Every biomarker in every panel explained: what it measures, why it matters, reference ranges, and evidence-based interventions. Reviewed by Ahmed Mahdi, DNP.
Our most comprehensive assessment with 29 tests covering 70+ individual biomarkers. This panel provides a 360-degree view of your hormonal health, thyroid function, metabolic status, cardiovascular risk, nutrient levels, and systemic inflammation. Ideal for men seeking a thorough baseline or those optimizing a testosterone replacement protocol.
Total testosterone measures the entire amount of testosterone circulating in the blood, including both the protein-bound fraction (attached to SHBG and albumin) and the small free fraction. Testosterone is the primary male androgen, produced mainly by the Leydig cells of the testes under LH stimulation, with a small contribution from the adrenal glands.
This is the foundational marker for evaluating male hormonal status. It is used to diagnose hypogonadism, monitor TRT efficacy, and assess symptoms such as fatigue, low libido, depression, and loss of muscle mass. It should always be interpreted alongside Free Testosterone and SHBG for a complete picture.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Total Testosterone | 250 – 1100 ng/dL | 500 – 900 ng/dL |
Fatigue, reduced libido, erectile dysfunction, depressed mood, brain fog, loss of lean muscle mass, increased body fat (especially visceral), decreased bone mineral density, and poor motivation. Causes include primary hypogonadism (testicular), secondary hypogonadism (pituitary/hypothalamic), aging, obesity, chronic opioid use, and metabolic syndrome.
Acne, oily skin, accelerated hair loss (androgenetic alopecia), irritability or aggression, and elevated risk of polycythemia (high red blood cell count). Excessively high levels are most often seen with exogenous testosterone use and require dose adjustment.
Free testosterone is the unbound, biologically active fraction of total testosterone — typically only 2–3% of the total. Unlike bound testosterone, free testosterone can enter cells, bind to androgen receptors, and exert direct physiological effects on muscle, bone, brain, and sexual function.
Free testosterone is often more clinically relevant than total testosterone because a man can have a "normal" total T yet experience hypogonadal symptoms if SHBG is elevated and free T is low. It is essential for accurate assessment of androgen status, especially in aging men, obese patients, or those with liver or thyroid conditions that alter SHBG.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Free Testosterone | 35.0 – 155.0 pg/mL (equilibrium dialysis) | 15 – 25 ng/dL (or 2–3% of total) |
The same symptom profile as low total testosterone — fatigue, reduced libido, erectile dysfunction, cognitive decline, and muscle wasting — but can occur even when total testosterone appears normal if SHBG is elevated. Common in aging, hyperthyroidism, and liver disease.
Similar to high total testosterone: acne, hair thinning, mood changes, and polycythemia risk. May occur when SHBG is abnormally low (insulin resistance, obesity), artificially inflating the free fraction relative to total.
SHBG is a glycoprotein produced primarily by the liver that binds testosterone, dihydrotestosterone (DHT), and estradiol with high affinity. It acts as a transport vehicle and regulator of bioavailable sex hormones. Approximately 65% of circulating testosterone is bound to SHBG and rendered inactive.
SHBG is critical for interpreting total testosterone results. High SHBG reduces free testosterone, potentially causing hypogonadal symptoms despite a "normal" total T. Low SHBG inflates free testosterone calculations. It is also a marker of metabolic health, insulin sensitivity, and liver function.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| SHBG | 10 – 50 nmol/L (males) | 20 – 40 nmol/L |
Insulin resistance, obesity, type 2 diabetes, hypothyroidism, PCOS (in females), and polycythemia risk. Low SHBG may falsely elevate calculated free testosterone and is independently associated with metabolic syndrome and cardiovascular risk.
Hyperthyroidism, liver disease (cirrhosis, hepatitis), aging, estrogen excess, and anticonvulsant use. Elevated SHBG effectively lowers bioavailable testosterone, causing hypogonadal symptoms even with adequate total testosterone production.
DHEA-S is the sulfated form of DHEA, the most abundant circulating steroid hormone in the body. Produced almost exclusively by the adrenal glands, it serves as a precursor to both testosterone and estrogen. DHEA-S levels peak in the mid-20s and decline steadily with age.
DHEA-S is a marker of adrenal function and overall hormonal reserve. It provides insight into the adrenal contribution to androgen production, stress resilience, immune function, and aging. Low levels are associated with fatigue, poor recovery, and accelerated aging.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| DHEA-S | Age-dependent: 20–29: 280–640, 30–39: 120–520, 40–49: 95–530, 50–59: 70–310, 60–69: 42–290, 70+: 28–175 mcg/dL | 250 – 400 μg/dL |
Adrenal insufficiency, chronic stress or burnout, aging, fatigue, weakened immunity, reduced libido, depression, and poor wound healing. Often seen alongside elevated cortisol in chronic stress states.
Adrenal tumors, congenital adrenal hyperplasia (CAH), PCOS (in females), or exogenous DHEA supplementation. Mildly elevated levels are usually not concerning in males.
Estradiol (E2) is the most potent and prevalent estrogen in the male body. In men, it is produced primarily through aromatization of testosterone by the aromatase enzyme, found in adipose tissue, the brain, and bone. The sensitive or ultrasensitive assay (LC/MS-MS) is required for accurate measurement in males, as standard immunoassays are designed for female ranges and produce unreliable results at lower concentrations.
Estradiol balance is critical for male health. Adequate E2 supports bone density, cardiovascular health, libido, and cognitive function. Both excessively low and high estradiol cause significant symptoms. It is essential to monitor E2 on TRT, as exogenous testosterone increases aromatization.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Estradiol (males, sensitive) | 8 – 35 pg/mL | 20 – 30 pg/mL |
Joint pain and stiffness, accelerated bone loss and osteoporosis risk, reduced libido (paradoxically), cognitive decline, fatigue, and poor mood. Often caused by over-use of aromatase inhibitors or very low body fat.
Gynecomastia (breast tissue growth), water retention and bloating, erectile dysfunction, emotional lability, mood swings, and increased body fat. Common causes include obesity (more aromatase in fat tissue), high-dose TRT, liver dysfunction, and alcohol excess.
Progesterone is a steroid hormone produced in small amounts by the adrenal glands and testes in men. Though often considered a "female hormone," progesterone plays important roles in male physiology — it is a precursor to cortisol and testosterone, and acts as a natural counterbalance to estrogen. It also has significant neuroprotective and calming effects via its metabolite allopregnanolone.
Progesterone helps assess adrenal function, estrogenic balance, and neurological well-being in men. Low levels are associated with anxiety, insomnia, and poor stress resilience. It is particularly useful for men experiencing mood or sleep disturbances alongside hormonal optimization.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Progesterone (males) | 0.2 – 1.4 ng/mL | 0.5 – 1.0 ng/mL |
Anxiety, insomnia, irritability, poor stress response, and estrogen dominance symptoms. May indicate adrenal fatigue or insufficient precursor hormone production.
Rare in males. When present, may indicate adrenal dysfunction, congenital adrenal hyperplasia, or exogenous progesterone use.
IGF-1 is a peptide hormone produced primarily by the liver in response to growth hormone (GH) stimulation. It mediates many of the anabolic effects attributed to growth hormone, including muscle growth, bone formation, tissue repair, and cellular regeneration. Unlike GH, which is released in pulsatile bursts, IGF-1 remains relatively stable throughout the day, making it a reliable surrogate marker for GH status.
IGF-1 assesses growth hormone sufficiency, recovery capacity, and anabolic potential. It is used to screen for GH deficiency, monitor GH or peptide therapy, and evaluate overall vitality. Optimal IGF-1 supports lean body composition, cognitive sharpness, and robust recovery.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| IGF-1 | Age-dependent: 20–25: 116–358, 26–30: 117–329, 31–35: 115–307, 36–40: 109–284, 41–45: 101–267, 46–50: 94–252, 51–55: 87–238, 56–60: 81–225, 61–65: 75–212, 66–70: 69–200 ng/mL | 150 – 250 ng/mL |
Growth hormone deficiency, poor recovery from exercise or injury, decreased muscle mass, increased body fat, thinning skin, accelerated aging, reduced cognitive function, and impaired sleep quality.
Acromegaly (if GH-producing pituitary adenoma), and theoretical concern for cancer cell proliferation at chronically elevated levels. Mild elevations from peptide therapy are generally well-tolerated.
FSH is a gonadotropin hormone produced by the anterior pituitary gland. In men, FSH acts on Sertoli cells in the testes to stimulate and maintain spermatogenesis (sperm production). It works in concert with LH, which stimulates testosterone production.
FSH helps distinguish between primary hypogonadism (testicular failure, where FSH is elevated) and secondary hypogonadism (pituitary/hypothalamic dysfunction, where FSH is low or inappropriately normal). It is essential for fertility assessment and is expected to be suppressed in men on exogenous testosterone or TRT.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| FSH | 1.6 – 8.0 mIU/mL | 2 – 8 mIU/mL |
Secondary hypogonadism, pituitary dysfunction, hypothalamic suppression, or exogenous testosterone use. Low FSH on TRT is expected and confirms hypothalamic-pituitary-gonadal (HPG) axis suppression. If fertility is desired, this is a concern.
Primary hypogonadism — the testes are failing and the pituitary is producing excess FSH in an attempt to stimulate them. Causes include testicular damage, Klinefelter syndrome, chemotherapy, radiation, and varicocele.
LH is a gonadotropin produced by the anterior pituitary gland. In men, LH binds to receptors on Leydig cells in the testes, directly stimulating testosterone synthesis. It is released in a pulsatile fashion and regulated by the hypothalamic-pituitary-gonadal (HPG) axis via GnRH and testosterone feedback loops.
Like FSH, LH is essential for differentiating primary from secondary hypogonadism. Elevated LH with low testosterone indicates the testes are failing. Low LH with low testosterone points to a pituitary or hypothalamic problem. LH is fully suppressed on exogenous testosterone.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| LH | 1.5 – 9.3 mIU/mL | 3 – 8 mIU/mL |
Secondary hypogonadism, pituitary dysfunction, hypothalamic suppression (stress, caloric restriction, opioids), or exogenous testosterone use. Suppressed LH on TRT is expected.
Primary hypogonadism — testicular failure with compensatory pituitary response. Causes include Klinefelter syndrome, orchitis, testicular trauma, chemotherapy, and varicocele.
Fasting insulin measures the amount of insulin circulating in the blood after an overnight fast. Insulin is a peptide hormone produced by the beta cells of the pancreas that facilitates glucose uptake into cells, regulates blood sugar, and plays a central role in fat storage, protein synthesis, and metabolic signaling.
Fasting insulin is one of the earliest markers of metabolic dysfunction — it rises years before fasting glucose or HbA1c become abnormal. Elevated fasting insulin indicates insulin resistance, the root driver of metabolic syndrome, type 2 diabetes, cardiovascular disease, and hormonal imbalances including low testosterone and elevated estrogen.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Fasting Insulin | 2.6 – 24.9 μIU/mL | 2 – 6 μIU/mL |
Type 1 diabetes (autoimmune beta cell destruction), late-stage type 2 diabetes with beta cell exhaustion, or prolonged fasting. Very low insulin with elevated glucose is a medical concern requiring immediate evaluation.
Insulin resistance, metabolic syndrome, prediabetes, PCOS, increased cardiovascular risk, non-alcoholic fatty liver disease (NAFLD), and chronic inflammation. High insulin drives fat storage, suppresses testosterone production, and accelerates aging.
Prolactin is a peptide hormone secreted by the anterior pituitary gland. While best known for its role in lactation in women, prolactin in men modulates immune function, dopamine signaling, and reproductive health. It is regulated by tonic dopamine inhibition — meaning dopamine keeps prolactin suppressed, and anything that reduces dopamine raises prolactin.
Elevated prolactin (hyperprolactinemia) is an important and often overlooked cause of low libido, erectile dysfunction, gynecomastia, and hypogonadism in men. It is essential to rule out prolactinoma (pituitary tumor) and medication-induced causes. Prolactin also helps assess pituitary function.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Prolactin | 2.0 – 18.0 ng/mL | 5 – 10 ng/mL |
Rare. May indicate pituitary insufficiency (hypopituitarism) or excessive dopamine agonist therapy. Isolated low prolactin is generally not clinically significant.
Prolactinoma (pituitary adenoma — most common cause of significant elevation), medications (antipsychotics, SSRIs, metoclopramide), hypothyroidism, chronic stress, and chest wall irritation. Symptoms include low libido, erectile dysfunction, gynecomastia, infertility, headaches, and visual field defects (if tumor is large).
Cortisol is the body's primary stress hormone, produced by the adrenal cortex in response to ACTH stimulation from the pituitary. It follows a diurnal rhythm, peaking in the early morning (6–8 AM) and reaching its nadir at midnight. Morning cortisol is measured to assess the peak of this rhythm and evaluate adrenal function.
Morning cortisol screens for adrenal insufficiency (Addison's disease) and Cushing's syndrome. In functional medicine, it is used to evaluate the HPA axis, chronic stress burden, and cortisol dysregulation that can suppress testosterone, impair thyroid function, disrupt sleep, and promote visceral fat accumulation.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Cortisol AM | 4.0 – 22.0 mcg/dL (AM specimen) | 10 – 15 μg/dL |
Adrenal insufficiency (primary or secondary), chronic HPA axis suppression, "adrenal fatigue" (functional cortisol insufficiency), chronic fatigue syndrome, poor stress tolerance, hypotension, and salt cravings.
Cushing's syndrome or disease, chronic psychological or physiological stress, anxiety disorders, insomnia, visceral fat accumulation, insulin resistance, immune suppression, and accelerated muscle catabolism.
TSH is produced by the anterior pituitary gland and acts on the thyroid gland to stimulate production and release of thyroid hormones (T4 and T3). It operates via a negative feedback loop — when thyroid hormones are low, TSH rises; when thyroid hormones are adequate, TSH decreases.
TSH is the primary screening marker for thyroid dysfunction. Thyroid health directly impacts energy, metabolism, body composition, mood, cognitive function, and testosterone production. Many men with "normal" TSH by conventional standards actually have suboptimal thyroid function when assessed by functional ranges.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| TSH | 0.40 – 4.50 uIU/mL | 0.5 – 2.0 mIU/L |
Hyperthyroidism (Graves' disease, toxic nodule), excessive thyroid medication dosing, or central hypothyroidism (rare, pituitary issue where TSH is inappropriately low despite low thyroid hormones).
Primary hypothyroidism (the thyroid gland is underperforming), Hashimoto's thyroiditis (autoimmune destruction), iodine deficiency, or recovery from non-thyroidal illness. Symptoms include fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, depression, and brain fog.
Free T4 measures the unbound, bioavailable fraction of thyroxine — the primary hormone produced by the thyroid gland. T4 is a prohormone that must be converted to the active hormone T3 by deiodinase enzymes in peripheral tissues (liver, kidneys, gut). About 80% of circulating thyroid hormone is T4.
Free T4 confirms thyroid hormone production capacity and helps differentiate causes of abnormal TSH. It is essential for monitoring thyroid medication dosing and assessing the thyroid gland's synthetic output independent of conversion efficiency.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Free T4 | 0.82 – 1.77 ng/dL | 1.0 – 1.5 ng/dL |
Hypothyroidism (primary or central), insufficient thyroid medication dosing, or pituitary dysfunction. Symptoms mirror hypothyroidism: fatigue, weight gain, cold intolerance, and cognitive sluggishness.
Hyperthyroidism, Graves' disease, excessive levothyroxine dosing, thyroiditis (transient inflammation releasing stored hormone), or biotin supplement interference with the assay.
Free T3 is the unbound, active form of triiodothyronine — the thyroid hormone that actually enters cells and activates nuclear receptors to regulate metabolism, energy production, body temperature, heart rate, and gene expression. Only about 20% of T3 is produced directly by the thyroid; the majority is converted from T4 in peripheral tissues.
Free T3 is the best indicator of cellular thyroid function and how the body is actually utilizing thyroid hormone. A patient can have normal TSH and Free T4 yet still experience hypothyroid symptoms if T4-to-T3 conversion is impaired — making Free T3 essential for complete thyroid assessment.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Free T3 | 2.3 – 4.2 pg/mL | 3.0 – 4.0 pg/mL |
Hypothyroidism, poor T4-to-T3 conversion (selenium, zinc, or iron deficiency), chronic illness (sick euthyroid syndrome), high cortisol, caloric restriction, and chronic inflammation. Symptoms include persistent fatigue despite "normal" TSH, cold hands/feet, brain fog, and weight loss resistance.
Hyperthyroidism, Graves' disease, T3 thyrotoxicosis, or excessive T3 supplementation (liothyronine). Symptoms include anxiety, palpitations, tremor, weight loss, heat intolerance, and insomnia.
Reverse T3 (rT3) is an inactive metabolite of T4. When the body is under stress, inflammation, or caloric restriction, it preferentially converts T4 into Reverse T3 instead of the active T3. Reverse T3 competes with T3 at the cellular receptor level but does not activate metabolic processes — effectively acting as a "brake" on thyroid function.
Reverse T3 explains why a patient can have normal TSH and Free T4 yet still feel hypothyroid. Elevated rT3 is a sign that the body is in a conservation or stress state, diverting thyroid hormone away from active metabolism. The Free T3 to Reverse T3 ratio is a critical clinical metric.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Reverse T3 | 9.2 – 24.1 ng/dL | 9 – 15 ng/dL |
| Free T3 / Reverse T3 Ratio | — | > 0.2 is optimal |
Rare and generally not clinically significant. Very low rT3 may be seen in hyperthyroidism where T4 is being preferentially converted to T3.
Chronic stress, high cortisol, systemic inflammation, caloric restriction or crash dieting, chronic illness (non-thyroidal illness syndrome), iron deficiency, and liver dysfunction. Symptoms mimic hypothyroidism despite "normal" standard thyroid labs.
TPO antibodies are autoantibodies directed against thyroid peroxidase, the key enzyme involved in thyroid hormone synthesis. Their presence indicates that the immune system is attacking the thyroid gland. TPO antibodies are the hallmark laboratory finding in Hashimoto's thyroiditis, the most common cause of hypothyroidism in developed countries.
TPO antibodies identify autoimmune thyroid disease, often years before overt hypothyroidism develops. Early detection allows proactive intervention to reduce antibody titers, slow thyroid destruction, and prevent progression to full thyroid failure. They also explain thyroid symptoms in patients with "normal" TSH.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| TPO Antibodies | < 9 IU/mL (negative) | < 2 IU/mL |
Hashimoto's thyroiditis (most common), Graves' disease, or general autoimmune predisposition. Elevated TPO antibodies confer a significantly increased lifetime risk of developing overt hypothyroidism and are associated with thyroid inflammation, nodules, and fluctuating thyroid function.
25-Hydroxy Vitamin D is the storage form of vitamin D measured in the blood and the best indicator of overall vitamin D status. Vitamin D functions as a secosteroid hormone influencing over 1,000 genes. It is synthesized in the skin upon UVB exposure and converted in the liver to 25(OH)D, then activated in the kidneys to 1,25-dihydroxyvitamin D (calcitriol).
Vitamin D deficiency is among the most prevalent nutrient insufficiencies worldwide and is linked to bone loss, depression, immune dysfunction, increased cancer risk, cardiovascular disease, and impaired testosterone production. Optimization is foundational to nearly every aspect of male health.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Vitamin D, 25-OH | 30 – 100 ng/mL | 50 – 80 ng/mL |
Bone loss and osteoporosis risk, depression, chronic fatigue, impaired immune function (frequent infections), increased cancer risk, muscle weakness, poor wound healing, and reduced testosterone levels. Extremely common in northern latitudes, darker skin tones, and indoor lifestyles.
Levels above 100 ng/mL carry toxicity risk including hypercalcemia, kidney stones, nausea, and soft tissue calcification. Toxicity is almost exclusively from supplementation, not sun exposure.
RBC magnesium measures the concentration of magnesium inside red blood cells, reflecting intracellular magnesium stores. This is far superior to standard serum magnesium, which only represents about 1% of total body magnesium and can appear normal even in the setting of significant intracellular depletion. Magnesium is a cofactor in over 600 enzymatic reactions.
Magnesium is essential for energy production (ATP), muscle and nerve function, blood sugar regulation, blood pressure control, sleep quality, and testosterone production. Deficiency is extremely common (estimated 50–80% of the population) and is associated with nearly every chronic disease.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Magnesium RBC | 4.2 – 6.8 mg/dL | 5.5 – 6.5 mg/dL |
Muscle cramps and spasms, anxiety, insomnia, heart palpitations or arrhythmias, migraines, insulin resistance, constipation, restless legs, poor exercise recovery, and elevated blood pressure. Depleted by stress, alcohol, medications (PPIs, diuretics), and processed food diets.
Rare from oral supplementation alone. Elevated levels typically indicate renal failure (inability to excrete magnesium) or excessive IV magnesium administration. Symptoms of toxicity include hypotension, respiratory depression, and cardiac conduction abnormalities.
Vitamin B12 is a water-soluble vitamin essential for DNA synthesis, red blood cell formation, neurological function, and methylation reactions. It is obtained exclusively from animal-source foods or supplementation. B12 requires intrinsic factor (produced by gastric parietal cells) for absorption in the ileum.
B12 deficiency causes irreversible neurological damage if left untreated, and is far more common than most clinicians recognize — particularly in patients taking metformin, proton pump inhibitors, or following plant-based diets. Conventional "normal" ranges are too broad, and functional deficiency often exists well within the standard reference range.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Vitamin B12 | 232 – 1245 pg/mL | 500 – 900 pg/mL |
Fatigue, peripheral neuropathy (numbness, tingling in hands/feet), cognitive decline and memory loss, depression, macrocytic anemia, elevated homocysteine, and glossitis. Common causes include pernicious anemia, metformin use, PPI use, vegan/vegetarian diet, malabsorption, and aging.
Rarely concerning from supplementation. Unexplained elevations may indicate liver disease (hepatitis, cirrhosis), myeloproliferative disorders, or kidney disease. The body generally excretes excess B12.
RBC folate measures the concentration of folate stored inside red blood cells, providing a more accurate assessment of long-term folate status than serum folate (which reflects recent intake only). Folate (vitamin B9) is essential for DNA synthesis, methylation, amino acid metabolism, and red blood cell production. It works closely with B12 in the methionine cycle.
Folate deficiency causes megaloblastic anemia, elevated homocysteine (cardiovascular and neurological risk), depression, and impaired DNA repair. RBC folate is the preferred measure because it reflects tissue stores over the preceding 2–3 months rather than recent dietary intake.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Folate RBC | > 280 ng/mL | 400 – 800 ng/mL |
Megaloblastic anemia, elevated homocysteine (cardiovascular risk), depression, cognitive impairment, and impaired DNA synthesis. Causes include poor dietary intake, malabsorption, alcoholism, MTHFR mutations, and medications (methotrexate, anticonvulsants).
Generally not harmful but may mask B12 deficiency (folate can correct the anemia of B12 deficiency while neurological damage progresses silently). Always check B12 alongside folate.
Ferritin is the primary iron storage protein in the body. A single ferritin molecule can store up to 4,500 iron atoms. Serum ferritin reflects total body iron stores and is the most sensitive and specific early marker of iron deficiency. However, ferritin is also an acute phase reactant, meaning it rises with inflammation, infection, and liver disease independent of iron status.
Ferritin is essential for diagnosing both iron deficiency (with or without anemia) and iron overload (hemochromatosis). Low ferritin is an extremely common and underdiagnosed cause of fatigue, hair loss, restless legs, and poor exercise performance. Elevated ferritin in the context of TRT requires monitoring as testosterone stimulates erythropoiesis.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Ferritin (males) | 30 – 400 ng/mL | 50 – 150 ng/mL |
Iron deficiency (even without frank anemia), fatigue, hair loss, restless legs syndrome, poor exercise tolerance, impaired cognitive function, brittle nails, and pagophagia (ice cravings). Causes include chronic blood loss, poor dietary intake, malabsorption, and celiac disease.
Hereditary hemochromatosis, chronic inflammation (ferritin is an acute phase reactant), liver disease, excessive iron supplementation, frequent red meat consumption, and alcohol abuse. Iron overload causes organ damage to the liver, heart, and pancreas.
This panel measures serum iron (the amount of iron circulating in the blood bound to transferrin), TIBC (Total Iron-Binding Capacity — reflecting transferrin availability), and transferrin saturation (the percentage of transferrin that is occupied by iron). Together, these markers provide a complete picture of iron transport and availability.
While ferritin reflects iron stores, the iron/TIBC panel reveals how iron is being transported and utilized in real time. It is essential for differentiating iron deficiency anemia from anemia of chronic disease, and for diagnosing iron overload conditions like hemochromatosis.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Serum Iron | 27 – 159 mcg/dL (males) | Mid-range, context-dependent |
| TIBC | 250 – 370 μg/dL | 250 – 370 μg/dL |
| Transferrin Saturation | 15 – 55% | 25 – 45% |
Iron deficiency — the body has low circulating iron and is upregulating transferrin production to capture more. Causes include blood loss, poor dietary intake, malabsorption, and chronic disease. Symptoms include fatigue, pallor, and shortness of breath.
Iron overload (hemochromatosis), chronic inflammation, liver disease, or excessive supplementation. High transferrin saturation above 45% raises concern for hemochromatosis and warrants genetic testing (HFE gene).
Homocysteine is a sulfur-containing amino acid produced as an intermediate in the methylation cycle — the conversion of methionine to cysteine. It is recycled back to methionine via B12- and folate-dependent enzymes (particularly MTHFR) or converted to cysteine via B6-dependent pathways. Elevated homocysteine indicates impaired methylation.
Elevated homocysteine is an independent risk factor for cardiovascular disease, stroke, deep vein thrombosis, cognitive decline, Alzheimer's disease, and pregnancy complications. It is a functional marker of B12, folate, and B6 status, and a key indicator of methylation efficiency — making it one of the most actionable biomarkers available.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Homocysteine | 0 – 10.4 umol/L | 6 – 8 μmol/L |
Not clinically significant. Very low homocysteine may be seen with over-supplementation of methyl donors but does not typically cause harm.
Cardiovascular disease risk (endothelial damage, accelerated atherosclerosis), B12 deficiency, folate deficiency, MTHFR mutations (C677T, A1298C), B6 deficiency, kidney disease, hypothyroidism, and cognitive decline. Each 5 μmol/L increase is associated with approximately 20% increased cardiovascular risk.
The Comprehensive Metabolic Panel is a group of 16 blood tests that provides a broad assessment of metabolic health, including kidney function, liver function, electrolyte balance, blood sugar, and protein status. Markers include: glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium, total protein, albumin, globulin, A/G ratio, total bilirubin, alkaline phosphatase (ALP), AST, and ALT.
The CMP serves as a foundational health screen. It detects kidney disease, liver damage, diabetes, electrolyte imbalances, and nutritional deficiencies. For men on TRT or other medications, regular CMP monitoring ensures no adverse effects on liver or kidney function.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Fasting Glucose | 65 – 99 mg/dL | 70 – 85 mg/dL |
| BUN | 6 – 24 mg/dL | 10 – 16 mg/dL |
| Creatinine | 0.76 – 1.27 mg/dL | 0.9 – 1.2 mg/dL |
| AST | 0 – 40 IU/L | < 25 IU/L |
| ALT | 0 – 44 IU/L | < 25 IU/L |
| Sodium | 134 – 144 mEq/L | 138 – 142 mEq/L |
| Potassium | 3.5 – 5.2 mEq/L | 4.0 – 4.5 mEq/L |
Elevated glucose (>100 mg/dL fasting): prediabetes concern; correlate with HbA1c and fasting insulin. Elevated AST/ALT: liver stress from alcohol, medications, NAFLD, or supplements. Elevated BUN/creatinine: kidney dysfunction, dehydration, or high-protein diet. Low albumin: malnutrition, liver disease, chronic inflammation.
HbA1c measures the percentage of hemoglobin molecules that have glucose permanently attached to them. Because red blood cells live approximately 90–120 days, HbA1c reflects average blood sugar control over the preceding 2–3 months. It is the gold standard for diagnosing and monitoring diabetes.
HbA1c provides a long-term picture of glycemic control that is not affected by day-to-day fluctuations or fasting status. It is critical for identifying prediabetes, monitoring diabetic control, and assessing metabolic health. Even "normal" HbA1c in the 5.5–5.6% range may indicate suboptimal metabolic function.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| HbA1c | < 5.7% normal | 5.7–6.4% prediabetes | ≥ 6.5% diabetes | 4.8 – 5.2% |
Chronic hyperglycemia, insulin resistance, prediabetes, or diabetes. Associated with increased cardiovascular risk, neuropathy, retinopathy, nephropathy, and accelerated aging via advanced glycation end-products (AGEs). Note: can be falsely low with hemolytic anemias or falsely high with iron deficiency.
Uric acid is the end product of purine metabolism, produced when the body breaks down purines from food (organ meats, shellfish, beer) and cellular turnover. It is filtered by the kidneys, and approximately 70% is excreted in urine while 30% is eliminated through the gut. Uric acid has both antioxidant properties (at normal levels) and pro-inflammatory effects (at elevated levels).
Elevated uric acid is far more than just a gout marker — it is an independent risk factor for hypertension, cardiovascular disease, metabolic syndrome, kidney disease, and type 2 diabetes. It is increasingly recognized as a central player in metabolic dysfunction, particularly when driven by excess fructose consumption.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Uric Acid | 3.4 – 7.0 mg/dL | 4.0 – 5.5 mg/dL |
May indicate oxidative stress (uric acid is a major extracellular antioxidant), Fanconi syndrome, Wilson's disease, or SIADH. Low uric acid is uncommon and often overlooked clinically.
Gout risk (crystal deposition in joints), kidney stone formation (urate stones), metabolic syndrome, hypertension, cardiovascular disease, non-alcoholic fatty liver disease, and fructose overconsumption. Also elevated with alcohol use, rapid weight loss, and cell turnover (tumor lysis).
GGT is an enzyme found primarily on the surface of liver cells and bile duct epithelium. It catalyzes the transfer of gamma-glutamyl groups and plays a central role in glutathione metabolism — specifically, the breakdown and recycling of glutathione, the body's master antioxidant. GGT is one of the most sensitive markers of liver stress.
GGT serves as an early warning for liver stress, bile duct obstruction, alcohol use, oxidative stress, and glutathione depletion. It is more sensitive than AST or ALT for detecting liver dysfunction and is an independent predictor of cardiovascular disease, metabolic syndrome, and all-cause mortality.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| GGT | 8 – 61 U/L | 10 – 30 U/L |
Possible magnesium or zinc deficiency (both are cofactors for GGT production). Hypothyroidism may also lower GGT. Very low levels are usually not a clinical concern.
Alcohol use (even moderate), liver disease (NAFLD, hepatitis, cirrhosis), bile duct obstruction, oxidative stress, glutathione depletion, medication effects (acetaminophen, statins, NSAIDs), obesity, and metabolic syndrome.
The Complete Blood Count with Differential is one of the most commonly ordered laboratory tests, measuring the cellular components of blood: red blood cells (RBC), white blood cells (WBC), platelets, hemoglobin, hematocrit, and RBC indices (MCV, MCH, MCHC, RDW). The differential breaks down WBC types: neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
The CBC screens for anemia, infection, immune dysfunction, blood cancers, clotting disorders, and nutritional deficiencies. For men on TRT, the CBC is essential for monitoring hematocrit and hemoglobin — testosterone stimulates erythropoiesis and can cause polycythemia, a potentially dangerous thickening of the blood.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| WBC | 3.4 – 10.8 x10E3/uL | 5.0 – 8.0 K/μL |
| RBC | 4.14 – 5.80 x10E6/uL | 4.7 – 5.5 M/μL |
| Hemoglobin | 12.6 – 17.7 g/dL | 14.0 – 16.5 g/dL |
| Hematocrit | 37.5 – 51.0% | 40 – 50% (flag >54% on TRT) |
| Platelets | 150 – 379 x10E3/uL | 200 – 300 K/μL |
| MCV | 79 – 97 fL | 85 – 95 fL |
High hematocrit (>54%) on TRT: polycythemia — requires TRT dose reduction, more frequent injections (smaller doses), or therapeutic phlebotomy. Increases risk of stroke, DVT, and PE. Low WBC: immune suppression, viral infections, bone marrow disorders. High WBC: infection, chronic stress, inflammation, smoking, corticosteroid use. Low MCV (<80): iron deficiency anemia. High MCV (>100): B12 or folate deficiency.
The standard lipid panel measures total cholesterol, LDL cholesterol (calculated), HDL cholesterol, triglycerides, and VLDL cholesterol. These lipoproteins transport cholesterol and triglycerides through the bloodstream. Cholesterol itself is essential for cell membranes, hormone production (including testosterone), vitamin D synthesis, and bile acid formation.
The lipid panel is the standard screening tool for cardiovascular risk assessment. Dyslipidemia — particularly elevated LDL, low HDL, and high triglycerides — is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). For optimal risk assessment, the lipid panel should be interpreted alongside ApoB, Lp(a), and hs-CRP.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Total Cholesterol | 100 – 199 mg/dL | 150 – 200 mg/dL |
| LDL Cholesterol | 0 – 99 mg/dL | < 100 mg/dL (lower if high risk) |
| HDL Cholesterol | > 39 mg/dL (males) | > 50 mg/dL |
| Triglycerides | 0 – 149 mg/dL | < 100 mg/dL |
| VLDL | 5 – 40 mg/dL | < 20 mg/dL |
Elevated LDL: increased atherogenic risk, especially when ApoB is also elevated. Low HDL: reduced reverse cholesterol transport, higher cardiovascular risk. Elevated triglycerides: metabolic syndrome, insulin resistance, increased VLDL and small dense LDL. The triglyceride/HDL ratio is a powerful surrogate for insulin resistance (optimal <1.5).
High-sensitivity CRP is a protein produced by the liver in response to systemic inflammation. Unlike standard CRP (which detects gross inflammation from infection or injury), the high-sensitivity assay measures very low levels of chronic, smoldering inflammation — the type that drives atherosclerosis, metabolic syndrome, and chronic disease.
hs-CRP is one of the strongest independent predictors of cardiovascular events, adding significant prognostic value beyond the lipid panel. Chronic low-grade inflammation is now recognized as a root driver of heart disease, diabetes, cancer, neurodegeneration, and aging. It is a critical marker for assessing and tracking systemic inflammatory burden.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| hs-CRP | < 3.0 mg/L | < 1.0 mg/L |
| Cardiovascular Risk: Low | < 1.0 mg/L | |
| Cardiovascular Risk: Moderate | 1.0 – 3.0 mg/L | |
| Cardiovascular Risk: High | > 3.0 mg/L | |
Chronic systemic inflammation, increased cardiovascular risk, metabolic syndrome, obesity (visceral fat produces inflammatory cytokines), autoimmune conditions, chronic infections, periodontal disease, sleep apnea, and chronic stress. Acute elevations may indicate recent infection or injury.
Apolipoprotein B is the primary structural protein on all atherogenic lipoprotein particles — including LDL, VLDL, IDL, and Lp(a). Each atherogenic particle carries exactly one ApoB molecule, making ApoB a direct count of the total number of particles that can penetrate the arterial wall and drive atherosclerosis. It is increasingly regarded as the single best lipid marker for cardiovascular risk.
ApoB is superior to LDL cholesterol for predicting cardiovascular risk because it measures particle number rather than cholesterol content. Two patients with identical LDL-C levels can have vastly different ApoB levels (and therefore different risk profiles), particularly in the setting of insulin resistance, metabolic syndrome, or diabetes where small dense LDL particles predominate.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| ApoB | < 130 mg/dL | < 80 mg/dL (some experts recommend < 60 mg/dL) |
Increased number of atherogenic particles, elevated cardiovascular and stroke risk, often discordant with LDL-C (ApoB may be high even when LDL appears normal). Associated with insulin resistance, metabolic syndrome, familial hypercholesterolemia, and high dietary saturated fat intake.
Lipoprotein(a) is a genetically determined lipoprotein particle consisting of an LDL-like particle with an additional apolipoprotein(a) protein attached via a disulfide bond. Its structure resembles plasminogen, giving it both atherogenic (plaque-building) and thrombogenic (clot-promoting) properties. Lp(a) levels are approximately 90% determined by genetics and remain relatively stable throughout life.
Lp(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease, aortic stenosis, and stroke — and it is not captured by standard lipid panels. Approximately 20% of the global population has elevated Lp(a). Because it is genetically fixed, it only needs to be measured once in a lifetime unless specific therapies are initiated.
| Measure | Desirable | High Risk |
|---|---|---|
| Lp(a) | < 30 mg/dL (or < 75 nmol/L) | > 50 mg/dL (or > 125 nmol/L) |
Significantly increased risk of heart attack, stroke, aortic stenosis, and peripheral artery disease — independent of LDL cholesterol levels. Lp(a) promotes arterial inflammation, plaque formation, and clot formation. It is one of the most underappreciated cardiovascular risk factors.
A comprehensive 20-test panel covering 50+ biomarkers across hormonal health, thyroid function, metabolic markers, cardiovascular risk, and key nutrients. This panel delivers the essential labs needed for a thorough male health evaluation, TRT monitoring, and metabolic optimization — at an accessible price point.
Total testosterone measures the entire amount of testosterone circulating in the blood, including both the protein-bound fraction (attached to SHBG and albumin) and the small free fraction. It is the primary male androgen, produced mainly by the Leydig cells of the testes.
The foundational marker for evaluating male hormonal status — used to diagnose hypogonadism, monitor TRT, and assess symptoms such as fatigue, low libido, and depression. Should always be interpreted alongside Free Testosterone and SHBG.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Total Testosterone | 250 – 1100 ng/dL | 500 – 900 ng/dL |
Fatigue, reduced libido, erectile dysfunction, depressed mood, brain fog, muscle loss, increased body fat, and decreased bone density. Causes include primary or secondary hypogonadism, aging, obesity, opioid use, and metabolic syndrome.
Acne, oily skin, accelerated hair loss, irritability, and polycythemia risk. Most commonly seen with exogenous testosterone use requiring dose adjustment.
Free testosterone is the unbound, biologically active fraction — typically only 2–3% of total testosterone. It enters cells, binds androgen receptors, and directly drives physiological effects on muscle, bone, brain, and sexual function.
Often more clinically relevant than total T. A man can have normal total T yet experience hypogonadal symptoms if SHBG is high and free T is low.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Free Testosterone | 35.0 – 155.0 pg/mL (equilibrium dialysis) | 15 – 25 ng/dL (or 2–3% of total) |
Same symptoms as low total T but can occur even with normal total T if SHBG is elevated. Common in aging, hyperthyroidism, and liver disease.
Acne, hair thinning, mood changes, polycythemia risk. May occur with abnormally low SHBG (insulin resistance, obesity).
A glycoprotein produced by the liver that binds testosterone, DHT, and estradiol. About 65% of circulating testosterone is bound to SHBG and rendered biologically inactive.
Critical for interpreting total testosterone. High SHBG reduces free T; low SHBG inflates it. Also a marker of metabolic health and insulin sensitivity.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| SHBG | 10 – 50 nmol/L (males) | 20 – 40 nmol/L |
Insulin resistance, obesity, hypothyroidism, metabolic syndrome. May falsely elevate calculated free testosterone.
Hyperthyroidism, liver disease, aging, estrogen excess. Causes hypogonadal symptoms despite adequate total T.
The sulfated form of DHEA — the most abundant circulating steroid hormone. Produced by the adrenal glands, it serves as a precursor to testosterone and estrogen. Levels peak in the mid-20s and decline with age.
Marker of adrenal function and hormonal reserve. Provides insight into adrenal androgen production, stress resilience, and biological aging.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| DHEA-S | Age-dependent: 20–29: 280–640, 30–39: 120–520, 40–49: 95–530, 50–59: 70–310, 60–69: 42–290, 70+: 28–175 mcg/dL | 250 – 400 μg/dL |
Adrenal insufficiency, chronic stress, aging, fatigue, and weakened immunity.
Adrenal tumors, congenital adrenal hyperplasia, or exogenous supplementation.
The most potent estrogen in the male body, produced through aromatization of testosterone. The sensitive assay (LC/MS-MS) is required for accurate male measurement.
Estradiol balance is critical — adequate E2 supports bones, cardiovascular health, libido, and cognition. Both low and high E2 cause significant symptoms. Must be monitored on TRT.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Estradiol (males, sensitive) | 8 – 35 pg/mL | 20 – 30 pg/mL |
Joint pain, bone loss, reduced libido, cognitive decline. Often from aromatase inhibitor overuse.
Gynecomastia, water retention, erectile dysfunction, mood swings. Common with obesity and high-dose TRT.
A steroid hormone produced by the adrenal glands and testes in men. Precursor to cortisol and testosterone, with neuroprotective and calming effects via its metabolite allopregnanolone.
Assesses adrenal function and estrogenic balance. Low levels associated with anxiety, insomnia, and poor stress resilience.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Progesterone (males) | 0.2 – 1.4 ng/mL | 0.5 – 1.0 ng/mL |
Anxiety, insomnia, irritability, poor stress response, estrogen dominance.
Rare in males; may indicate adrenal dysfunction.
A peptide hormone produced by the liver in response to growth hormone. Mediates GH's anabolic effects including muscle growth, tissue repair, and cellular regeneration. Remains stable throughout the day, making it a reliable GH surrogate.
Assesses growth hormone sufficiency, recovery capacity, and anabolic potential. Used to screen for GH deficiency and monitor peptide therapy.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| IGF-1 | Age-dependent: 20–25: 116–358, 26–30: 117–329, 31–35: 115–307, 36–40: 109–284, 41–45: 101–267, 46–50: 94–252, 51–55: 87–238, 56–60: 81–225, 61–65: 75–212, 66–70: 69–200 ng/mL | 150 – 250 ng/mL |
GH deficiency, poor recovery, decreased muscle mass, increased body fat, accelerated aging.
Acromegaly risk and theoretical cancer proliferation concern at chronically elevated levels.
A gonadotropin from the anterior pituitary that stimulates Sertoli cells in the testes to maintain spermatogenesis.
Distinguishes primary from secondary hypogonadism. Essential for fertility assessment. Suppressed on exogenous testosterone.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| FSH | 1.6 – 8.0 mIU/mL | 2 – 8 mIU/mL |
Secondary hypogonadism, pituitary dysfunction, or TRT-induced suppression.
Primary hypogonadism — testicular failure (Klinefelter syndrome, chemotherapy, varicocele).
A gonadotropin that stimulates Leydig cells in the testes to produce testosterone. Released in pulsatile fashion and regulated by the HPG axis.
Differentiates primary from secondary hypogonadism. Elevated LH with low T indicates testicular failure; low LH with low T suggests pituitary/hypothalamic dysfunction.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| LH | 1.5 – 9.3 mIU/mL | 3 – 8 mIU/mL |
Secondary hypogonadism, pituitary dysfunction, or exogenous testosterone use.
Primary hypogonadism — testicular failure with compensatory pituitary response.
Produced by the anterior pituitary, TSH stimulates the thyroid gland to produce T4 and T3. It operates via negative feedback — rising when thyroid hormones are low.
Primary screening marker for thyroid dysfunction. Thyroid health directly impacts energy, metabolism, body composition, mood, and testosterone production.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| TSH | 0.40 – 4.50 uIU/mL | 0.5 – 2.0 mIU/L |
Hyperthyroidism, excessive thyroid medication, or Graves' disease.
Hypothyroidism, Hashimoto's thyroiditis, iodine deficiency. Symptoms: fatigue, weight gain, cold intolerance, depression.
The unbound fraction of thyroxine — the primary hormone produced by the thyroid. T4 is a prohormone converted to active T3 by deiodinase enzymes in peripheral tissues.
Confirms thyroid production capacity and helps differentiate causes of abnormal TSH. Essential for thyroid medication dose monitoring.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Free T4 | 0.82 – 1.77 ng/dL | 1.0 – 1.5 ng/dL |
Hypothyroidism or pituitary dysfunction.
Hyperthyroidism, Graves' disease, or excessive levothyroxine.
Measures circulating insulin after an overnight fast. Insulin facilitates glucose uptake, regulates blood sugar, and plays a central role in fat storage and metabolic signaling.
One of the earliest markers of metabolic dysfunction — rising years before glucose or HbA1c become abnormal. Elevated insulin indicates insulin resistance, the root driver of metabolic syndrome and hormonal imbalance.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Fasting Insulin | 2.6 – 24.9 μIU/mL | 2 – 6 μIU/mL |
Type 1 diabetes or late-stage beta cell exhaustion.
Insulin resistance, metabolic syndrome, prediabetes, NAFLD, and increased cardiovascular risk. High insulin suppresses testosterone and promotes fat storage.
The storage form of vitamin D and the best indicator of overall vitamin D status. Functions as a secosteroid hormone influencing over 1,000 genes involved in immunity, bone health, mood, and hormone production.
Deficiency is linked to bone loss, depression, immune dysfunction, cancer risk, and impaired testosterone production. Optimization is foundational to male health.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Vitamin D, 25-OH | 30 – 100 ng/mL | 50 – 80 ng/mL |
Bone loss, depression, fatigue, poor immunity, increased cancer risk, and reduced testosterone.
Toxicity above 100 ng/mL — hypercalcemia, kidney stones.
Measures intracellular magnesium — far superior to serum magnesium (which reflects only ~1% of total body stores). Magnesium is a cofactor in 600+ enzymatic reactions including energy production, muscle function, and testosterone synthesis.
Deficiency is extremely common (50–80% of the population) and associated with muscle cramps, anxiety, insomnia, insulin resistance, and nearly every chronic disease.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Magnesium RBC | 4.2 – 6.8 mg/dL | 5.5 – 6.5 mg/dL |
Muscle cramps, anxiety, insomnia, arrhythmias, migraines, insulin resistance, and poor recovery.
Rare from supplementation; typically renal failure.
A sulfur-containing amino acid produced in the methylation cycle. Elevated levels indicate impaired methylation and B-vitamin deficiency. Recycled to methionine via B12/folate-dependent enzymes (MTHFR).
Independent risk factor for cardiovascular disease, stroke, cognitive decline, and Alzheimer's. Functional marker of B12, folate, and B6 status — one of the most actionable biomarkers available.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Homocysteine | 0 – 10.4 umol/L | 6 – 8 μmol/L |
Not clinically significant.
Cardiovascular risk, B12/folate deficiency, MTHFR mutations, kidney disease, and cognitive decline.
Essential for DNA synthesis, red blood cell formation, neurological function, and methylation. Obtained from animal foods and requires intrinsic factor for absorption.
Deficiency causes irreversible neurological damage and is common in metformin users, PPI users, and plant-based dieters. Functional deficiency exists well within the conventional "normal" range.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Vitamin B12 | 232 – 1245 pg/mL | 500 – 900 pg/mL |
Fatigue, neuropathy, cognitive decline, macrocytic anemia, depression, and elevated homocysteine.
Rarely concerning from supplementation; may indicate liver disease if unexplained.
The primary iron storage protein. Serum ferritin reflects total body iron stores and is the most sensitive early marker of iron deficiency. Also an acute phase reactant that rises with inflammation.
Essential for diagnosing iron deficiency (even without anemia) and iron overload. Low ferritin is an extremely common and underdiagnosed cause of fatigue, hair loss, and restless legs.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Ferritin (males) | 30 – 400 ng/mL | 50 – 150 ng/mL |
Iron deficiency, fatigue, hair loss, restless legs, and poor exercise tolerance.
Hemochromatosis, inflammation, liver disease, or excessive supplementation.
A group of 16 blood tests assessing metabolic health: kidney function, liver function, electrolyte balance, blood sugar, and protein status. Includes glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium, total protein, albumin, globulin, A/G ratio, bilirubin, ALP, AST, and ALT.
Foundational health screen detecting kidney disease, liver damage, diabetes, and electrolyte imbalances. Essential for men on TRT or other medications.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Fasting Glucose | 65 – 99 mg/dL | 70 – 85 mg/dL |
| AST | 0 – 40 IU/L | < 25 IU/L |
| ALT | 0 – 44 IU/L | < 25 IU/L |
| BUN | 6 – 24 mg/dL | 10 – 16 mg/dL |
Glucose >100: prediabetes concern. Elevated AST/ALT: liver stress. Elevated creatinine: kidney dysfunction or dehydration.
Measures the percentage of hemoglobin with glucose attached, reflecting average blood sugar over the preceding 2–3 months. The gold standard for diagnosing and monitoring diabetes.
Provides long-term glycemic control picture unaffected by daily fluctuations. Critical for identifying prediabetes and assessing metabolic health.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| HbA1c | < 5.7% normal | 5.7–6.4% prediabetes | ≥ 6.5% diabetes | 4.8 – 5.2% |
Chronic hyperglycemia, insulin resistance, prediabetes, or diabetes. Increased cardiovascular risk and accelerated aging.
Measures cellular blood components: RBC, WBC, platelets, hemoglobin, hematocrit, and indices. The differential breaks down WBC into neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
Screens for anemia, infection, and immune dysfunction. Essential on TRT — testosterone stimulates erythropoiesis and can cause dangerous polycythemia (hematocrit >54%).
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Hemoglobin | 12.6 – 17.7 g/dL | 14.0 – 16.5 g/dL |
| Hematocrit | 37.5 – 51.0% | 40 – 50% (flag >54% on TRT) |
| WBC | 3.4 – 10.8 x10E3/uL | 5.0 – 8.0 K/μL |
Hematocrit >54% on TRT: requires dose reduction or phlebotomy. Low MCV (<80): iron deficiency. High MCV (>100): B12/folate deficiency.
Measures total cholesterol, LDL, HDL, triglycerides, and VLDL — lipoproteins that transport cholesterol and triglycerides through the bloodstream.
Standard cardiovascular risk screening. Dyslipidemia is a major modifiable risk factor for atherosclerosis. Best interpreted with ApoB, Lp(a), and hs-CRP.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| LDL | 0 – 99 mg/dL | < 100 mg/dL |
| HDL | > 39 mg/dL (males) | > 50 mg/dL |
| Triglycerides | 0 – 149 mg/dL | < 100 mg/dL |
Elevated LDL: atherogenic risk. Low HDL: reduced reverse cholesterol transport. High triglycerides: metabolic syndrome. TG/HDL ratio <1.5 is optimal.
A liver-produced protein measuring chronic, low-grade systemic inflammation — the type driving atherosclerosis, metabolic syndrome, and chronic disease.
One of the strongest independent predictors of cardiovascular events, adding significant value beyond lipid panels alone.
| Measure | Risk Level | Value |
|---|---|---|
| Low Risk | Optimal | < 1.0 mg/L |
| Moderate Risk | Quest Diagnostics Range | 1.0 – 3.0 mg/L |
| High Risk | Elevated | > 3.0 mg/L |
Chronic inflammation, cardiovascular risk, metabolic syndrome, obesity, autoimmune conditions, sleep apnea, or chronic stress.
The primary structural protein on all atherogenic lipoprotein particles (LDL, VLDL, IDL, Lp(a)). Each particle carries exactly one ApoB molecule — making it a direct particle count and the single best lipid marker for cardiovascular risk.
Superior to LDL-C for predicting cardiovascular events because it measures particle number, not cholesterol content. Two patients with identical LDL-C can have vastly different ApoB and risk profiles.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| ApoB | < 130 mg/dL | < 80 mg/dL (some recommend < 60) |
Increased atherogenic particle burden and cardiovascular risk. Often discordant with LDL-C in insulin resistance and metabolic syndrome.
A genetically determined lipoprotein with both atherogenic and thrombogenic properties. Levels are ~90% genetic and stable throughout life. Its structure resembles plasminogen, giving it clot-promoting properties unique among lipoproteins.
Independent, causal cardiovascular risk factor not captured by standard lipid panels. About 20% of the population has elevated Lp(a). Only needs to be measured once in a lifetime.
| Measure | Desirable | High Risk |
|---|---|---|
| Lp(a) | < 30 mg/dL (< 75 nmol/L) | > 50 mg/dL (> 125 nmol/L) |
Significantly increased risk of heart attack, stroke, and aortic stenosis — independent of LDL cholesterol.
Seven specialized tests covering 15+ biomarkers that go beyond standard panels. This panel explores advanced metabolic markers, cardiovascular particle analysis, genetic lipid risk, and environmental toxin burden. Ideal as an add-on to our Complete or Ultimate panels for men seeking the deepest possible insight into their health.
Adiponectin is a protein hormone secreted by adipose (fat) tissue that plays a protective role in metabolic health. Unlike most adipokines, adiponectin levels are inversely related to body fat — the leaner and more metabolically healthy you are, the higher your adiponectin. It enhances insulin sensitivity, reduces inflammation, and protects blood vessel walls from atherosclerosis.
Adiponectin is a powerful predictor of metabolic syndrome, type 2 diabetes, and cardiovascular disease risk. Low levels indicate visceral adiposity and insulin resistance even when BMI appears normal. It provides a deeper metabolic assessment than standard glucose or insulin markers alone.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Adiponectin (males) | 4 – 26 mcg/mL | 10 – 20 μg/mL |
Obesity (especially visceral), metabolic syndrome, insulin resistance, type 2 diabetes risk, cardiovascular disease risk, non-alcoholic fatty liver disease, and chronic low-grade inflammation.
Generally protective and associated with leanness, insulin sensitivity, and reduced cardiovascular risk. Very high levels in underweight individuals may warrant evaluation for underlying conditions.
1,5-Anhydroglucitol (1,5-AG) is a naturally occurring monosaccharide that competes with glucose for renal reabsorption. When blood glucose spikes above the renal threshold (~180 mg/dL), glucose displaces 1,5-AG in the kidneys, causing 1,5-AG to be excreted in urine and its blood levels to drop. This makes it a sensitive, real-time marker of glycemic variability and glucose excursions.
1,5-AG detects glucose spikes that HbA1c completely misses. A patient can have a normal HbA1c (good average) yet experience damaging postprandial glucose spikes that 1,5-AG reveals. It is the best blood marker for glycemic variability — a key driver of oxidative stress, endothelial damage, and diabetic complications.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| 1,5-Anhydroglucitol | 10.7 – 32.0 mcg/mL (males) | > 14 μg/mL |
Recent glucose excursions and spikes (even if HbA1c is normal), poor glycemic control, prediabetes with postprandial hyperglycemia, and increased oxidative stress. Lower 1,5-AG correlates with greater glucose variability.
Uric acid is the end product of purine metabolism. It has antioxidant properties at normal levels but becomes pro-inflammatory when elevated. Approximately 70% is excreted by the kidneys and 30% through the gut.
Elevated uric acid is an independent risk factor for hypertension, cardiovascular disease, metabolic syndrome, kidney disease, and type 2 diabetes — far more than just a gout marker. It is increasingly recognized as a central player in metabolic dysfunction driven by excess fructose.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Uric Acid | 3.4 – 7.0 mg/dL | 4.0 – 5.5 mg/dL |
May indicate oxidative stress (uric acid is a major antioxidant), Fanconi syndrome, or Wilson's disease. Uncommon and often clinically overlooked.
Gout risk, kidney stone formation, metabolic syndrome, hypertension, cardiovascular disease, NAFLD, and fructose overconsumption.
TMAO is a metabolite produced when gut bacteria convert dietary choline, carnitine, and betaine into trimethylamine (TMA), which is then oxidized to TMAO in the liver by FMO3 enzymes. TMAO promotes atherosclerosis by enhancing cholesterol accumulation in artery walls, increasing platelet reactivity, and promoting inflammation.
Elevated TMAO is an independent risk factor for cardiovascular disease, stroke, and kidney disease progression. It reflects the intersection of diet, gut microbiome health, and cardiovascular risk — providing insight that standard lipid panels cannot.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| TMAO | < 6.2 umol/L low risk; 6.2–9.9 moderate; ≥ 10.0 high | < 4 μmol/L |
Increased cardiovascular risk, gut dysbiosis (overgrowth of TMA-producing bacteria), kidney disease progression, and enhanced platelet aggregation and thrombosis risk.
The NMR (Nuclear Magnetic Resonance) LipoProfile uses advanced spectroscopy to measure the actual number and size of lipoprotein particles — rather than just the cholesterol content carried within them. It quantifies LDL particle number (LDL-P), LDL particle size (small dense vs. large buoyant), HDL particle number, and VLDL particle characteristics.
Standard lipid panels measure cholesterol content, but cardiovascular risk is driven by particle number. Two patients with identical LDL-C can have dramatically different LDL particle counts. The NMR LipoProfile provides superior cardiovascular risk stratification, especially in metabolic syndrome and diabetes where small dense LDL predominates.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| LDL Particle Number (LDL-P) | < 1138 nmol/L | < 1,000 nmol/L (ideal < 700) |
| Small LDL-P | < 142 nmol/L | Minimize (higher = more atherogenic) |
| LDL Particle Size | Pattern A (large) vs B (small) | Pattern A preferred |
High LDL-P: increased atherogenic risk regardless of LDL-C. Pattern B (small dense LDL): more particles penetrate arterial walls, higher oxidation susceptibility, and stronger association with insulin resistance, metabolic syndrome, and cardiovascular events. Pattern A (large buoyant): relatively lower risk.
Apolipoprotein E (ApoE) is a protein involved in cholesterol transport and metabolism, particularly the clearance of triglyceride-rich lipoproteins from the bloodstream. The ApoE gene has three common alleles — E2, E3, and E4 — producing six possible genotype combinations. This is a one-time genetic test.
ApoE genotype influences lipid metabolism, Alzheimer's disease risk, and cardiovascular risk. It guides dietary and pharmacological decisions: E4 carriers may respond more dramatically to dietary saturated fat, may benefit from earlier statin use, and carry increased Alzheimer's risk requiring proactive neuroprotective strategies.
| Genotype | Lipid Impact | Clinical Significance |
|---|---|---|
| E2/E2 | Lowest LDL, highest triglycerides | Type III hyperlipoproteinemia risk |
| E3/E3 | Most common, "normal" metabolism | Standard lipid metabolism |
| E3/E4 or E4/E4 | Higher LDL, enhanced fat absorption | Increased Alzheimer's and cardiovascular risk |
E4 carriers (approximately 25% of the population) have increased LDL cholesterol, enhanced intestinal fat absorption, impaired amyloid-beta clearance in the brain (Alzheimer's risk), and greater sensitivity to dietary saturated fat. E4/E4 homozygotes carry 10–15x increased Alzheimer's risk.
This panel measures blood levels of four toxic heavy metals: arsenic, cadmium, lead, and mercury. These are environmental toxins that accumulate in the body over time through contaminated water, food, occupational exposure, dental amalgams, and industrial pollution. Even low-level chronic exposure causes significant health damage.
Heavy metal toxicity is an underdiagnosed cause of fatigue, cognitive decline, neuropathy, hormonal disruption, kidney damage, and cancer risk. Chronic low-level exposure disrupts endocrine function, impairs mitochondrial energy production, and increases oxidative stress — all relevant to men seeking hormonal optimization.
| Metal | Quest Diagnostics Range | Optimal (Functional) |
|---|---|---|
| Arsenic | 0 – 23 mcg/L | As low as possible |
| Cadmium | 0 – 6.5 mcg/L | < 1.0 μg/L |
| Lead | < 5.0 mcg/dL | < 2 μg/dL |
| Mercury | 0 – 14.9 mcg/L | < 5 μg/L |
Arsenic: contaminated water, rice, occupational exposure — carcinogenic, cardiovascular toxin. Cadmium: cigarette smoke, industrial exposure — kidney damage, bone loss, prostate cancer risk. Lead: old paint, contaminated soil, plumbing — cognitive decline, neuropathy, hypertension, kidney damage. Mercury: seafood (methylmercury), dental amalgams — neurological damage, fatigue, tremor, cognitive impairment.
A focused 5-test panel targeting 7 biomarkers at the core of methylation — one of the body's most critical biochemical processes. Methylation governs DNA repair, detoxification, neurotransmitter production, and homocysteine metabolism. This panel identifies MTHFR genetic variants and assesses functional B-vitamin status to guide precise supplementation.
MTHFR (methylenetetrahydrofolate reductase) is a gene encoding the enzyme that converts folate into its active, usable form — 5-methyltetrahydrofolate (5-MTHF). This active folate is essential for converting homocysteine back to methionine in the methylation cycle. Two common mutations are tested: C677T and A1298C.
MTHFR mutations reduce the enzyme's ability to activate folate, leading to impaired methylation — a foundational biochemical process governing DNA repair, detoxification, neurotransmitter synthesis, and cardiovascular health. Identifying mutations allows for precise, targeted supplementation that bypasses the genetic bottleneck.
| Variant | Status | Enzyme Activity Reduction |
|---|---|---|
| C677T Heterozygous | One copy | ~35% reduced activity |
| C677T Homozygous | Two copies | ~70% reduced activity |
| A1298C Heterozygous | One copy | Milder reduction |
| A1298C Homozygous | Two copies | Moderate reduction |
| Compound Heterozygous (C677T + A1298C) | One of each | Significant reduction |
MTHFR mutations are associated with elevated homocysteine, impaired detoxification, increased cardiovascular and stroke risk, depression and anxiety (impaired neurotransmitter methylation), neural tube defect risk, recurrent pregnancy loss, and poor drug metabolism. The clinical significance depends on the specific variant and whether homocysteine is actually elevated.
Homocysteine is a sulfur-containing amino acid produced as an intermediate in the methylation cycle. It is recycled back to methionine via B12- and folate-dependent enzymes (including MTHFR) or converted to cysteine via B6-dependent pathways. Elevated homocysteine is the primary functional consequence of MTHFR mutations and B-vitamin deficiency.
In this methylation-focused panel, homocysteine serves as the key functional readout of methylation efficiency. It directly answers whether MTHFR mutations and B-vitamin status are producing clinical consequences. It is an independent risk factor for cardiovascular disease, stroke, cognitive decline, and Alzheimer's disease.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Homocysteine | 0 – 10.4 umol/L | 6 – 8 μmol/L |
Not clinically significant. May reflect adequate or excessive methylation support supplementation.
Impaired methylation, B12 deficiency, folate deficiency, MTHFR mutations, B6 deficiency, kidney disease, hypothyroidism, and increased cardiovascular and neurological risk. Each 5 μmol/L increase raises cardiovascular risk by approximately 20%.
Vitamin B12 is essential for the methylation cycle — specifically as a cofactor for the enzyme methionine synthase, which converts homocysteine back to methionine. It is also required for DNA synthesis, red blood cell formation, myelin sheath maintenance, and neurological function.
In this methylation panel, B12 is assessed as a critical methylation cofactor. Deficiency impairs the remethylation of homocysteine, leading to elevated homocysteine and downstream methylation failure. Serum B12 can appear "normal" while functional/cellular deficiency exists — which is why MMA is included as a confirmatory marker.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Vitamin B12 | 232 – 1245 pg/mL | 500 – 900 pg/mL |
Impaired methylation, elevated homocysteine, fatigue, peripheral neuropathy, cognitive decline, depression, macrocytic anemia, and glossitis. Common causes: pernicious anemia, metformin use, PPI use, vegan diet, aging, and malabsorption.
Rarely concerning from supplementation. Unexplained elevations may indicate liver disease or myeloproliferative disorders.
RBC folate measures long-term folate stores inside red blood cells, reflecting status over the preceding 2–3 months. Folate (vitamin B9) is the substrate that MTHFR converts into the active 5-MTHF form needed for methylation. It works in concert with B12 to recycle homocysteine.
In this methylation panel, RBC folate assesses whether adequate folate substrate is available for MTHFR to process. Even with a normal MTHFR gene, low folate intake will impair methylation. Conversely, MTHFR mutation carriers need methylfolate (5-MTHF) rather than synthetic folic acid, which they cannot efficiently convert.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Folate RBC | > 280 ng/mL | 400 – 800 ng/mL |
Impaired methylation, elevated homocysteine, megaloblastic anemia, depression, cognitive impairment, and increased cardiovascular risk. Causes include poor dietary intake, MTHFR mutations (inability to utilize folic acid), alcoholism, and medications.
Generally not harmful but may mask B12 deficiency. Always check B12 alongside folate — folate corrects the anemia of B12 deficiency while neurological damage progresses silently.
Methylmalonic acid is a metabolite that accumulates when vitamin B12 is insufficient at the cellular level. B12 serves as a cofactor for the enzyme methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the mitochondria. When B12 is deficient, this conversion stalls and MMA accumulates in the blood.
MMA is the most specific and sensitive marker of functional B12 deficiency — more reliable than serum B12 alone. A patient can have a "normal" serum B12 yet have elevated MMA, indicating that B12 is not reaching cells in adequate amounts. This is particularly important in the context of methylation assessment, where cellular B12 sufficiency is critical.
| Measure | Quest Diagnostics Range | Optimal / Functional Range |
|---|---|---|
| Methylmalonic Acid | 0 – 378 nmol/L | < 150 nmol/L |
Functional B12 deficiency at the cellular level, even when serum B12 appears normal. Indicates impaired mitochondrial function, impaired methylation, and risk of neurological damage. Mildly elevated MMA can also be seen in renal insufficiency (reduced excretion) and gut bacterial overgrowth (bacterial MMA production).
$249 • 10 tests • 20+ biomarkers • Comprehensive hormonal assessment
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 250 – 1100 ng/dL (adult males) |
| Optimal/Functional Range | 500 – 900 ng/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 35.0 – 155.0 pg/mL (equilibrium dialysis) |
| Optimal/Functional Range | 100 – 200 pg/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 10 – 50 nmol/L (adult males) |
| Optimal/Functional Range | 20 – 40 nmol/L |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | Age-dependent (mcg/dL): 20-29: 280–640 | 30-39: 120–520 40-49: 95–530 | 50-59: 70–310 60-69: 42–290 | 70+: 28–175 |
| Optimal/Functional Range | Upper half of age-adjusted range |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 8.0 – 35.0 pg/mL (males, LC/MS) |
| Optimal/Functional Range | 20 – 30 pg/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.2 – 1.4 ng/mL (males) |
| Optimal/Functional Range | 0.5 – 1.2 ng/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | Age-dependent (ng/mL): 20-29: 116–358 | 30-39: 106–255 40-49: 94–267 | 50-59: 71–234 60-69: 64–188 | 70-79: 51–187 |
| Optimal/Functional Range | Upper third of age-adjusted range |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 1.6 – 8.0 mIU/mL (males) |
| Optimal/Functional Range | 3.0 – 8.0 mIU/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 1.5 – 9.3 mIU/mL (males) |
| Optimal/Functional Range | 3.0 – 6.0 mIU/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.40 – 4.50 uIU/mL |
| Optimal/Functional Range | 0.5 – 2.5 uIU/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.82 – 1.77 ng/dL |
| Optimal/Functional Range | 1.1 – 1.5 ng/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.6 – 24.9 uIU/mL |
| Optimal/Functional Range | <5 – 8 uIU/mL |
| HOMA-IR (calculated) | <1.0 ideal |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.0 – 18.0 ng/mL (males) |
| Optimal/Functional Range | 3 – 10 ng/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range (AM) | 4.0 – 22.0 mcg/dL |
| Optimal/Functional Range | 10 – 18 mcg/dL |
$179 • 7 tests • 30+ biomarkers • Essential safety labs for testosterone therapy
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 250 – 1100 ng/dL (adult males) |
| Optimal/Functional Range (on TRT, at trough) | 500 – 900 ng/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 35.0 – 155.0 pg/mL (equilibrium dialysis) |
| Optimal/Functional Range | 100 – 200 pg/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 10 – 50 nmol/L (adult males) |
| Optimal/Functional Range | 20 – 40 nmol/L |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 8.0 – 35.0 pg/mL (males, LC/MS) |
| Optimal/Functional Range on TRT | 20 – 30 pg/mL |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| WBC | 3.4 – 10.8 x10E3/uL | 5.0 – 7.0 |
| RBC | 4.14 – 5.80 M/uL | 4.5 – 5.5 |
| Hemoglobin | 12.6 – 17.7 g/dL | 14.5 – 16.5 |
| Hematocrit | 37.5 – 51.0% | 42 – 50% |
| MCV | 79 – 97 fL | 82 – 92 |
| Platelets | 150 – 379 x10E3/uL | 200 – 300 |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| Glucose (fasting) | 65 – 99 mg/dL | 75 – 90 |
| BUN | 6 – 24 mg/dL | 10 – 16 |
| Creatinine | 0.76 – 1.27 mg/dL | 0.9 – 1.2 |
| Sodium | 134 – 144 mmol/L | 137 – 142 |
| Potassium | 3.5 – 5.2 mmol/L | 4.0 – 4.8 |
| Chloride | 96 – 106 mmol/L | 100 – 104 |
| CO2 | 20 – 29 mmol/L | 23 – 28 |
| Calcium | 8.7 – 10.2 mg/dL | 9.2 – 10.0 |
| Total Protein | 6.0 – 8.5 g/dL | 6.5 – 7.5 |
| Albumin | 3.5 – 5.5 g/dL | 4.2 – 5.0 |
| Globulin | 1.5 – 4.5 g/dL | 2.0 – 3.5 |
| A/G Ratio | 1.2 – 2.2 | 1.5 – 2.0 |
| Bilirubin, Total | 0.0 – 1.2 mg/dL | 0.2 – 1.0 |
| ALP | 44 – 147 IU/L | 50 – 100 |
| AST | 0 – 40 U/L | 10 – 26 |
| ALT | 0 – 44 U/L | 10 – 26 |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| Total Cholesterol | 100 – 199 mg/dL | 150 – 200 |
| LDL | 0 – 99 mg/dL | <100 |
| HDL | >39 mg/dL (men) | >50 |
| Triglycerides | 0 – 149 mg/dL | <100 |
| VLDL | 5 – 40 mg/dL | <20 |
| TG/HDL Ratio | — | <2.0 |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.0 – 18.0 ng/mL (males) |
| Optimal/Functional Range | 3 – 10 ng/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | Age-based (ng/mL): 40-49: 0–2.5 | 50-59: 0–3.5 60-69: 0–4.5 | 70-79: 0–6.5 |
| Optimal/Functional Range (under 50) | <1.0 ng/mL |
| Optimal/Functional Range (50-60) | <2.0 ng/mL |
| Concerning velocity | Rise >1.4 ng/mL above baseline |
$199 • 9 tests • 25+ biomarkers • Uncover the root causes of stubborn weight
| Measure | Range |
|---|---|
| Normal | <5.7% |
| Optimal | 4.8 – 5.3% |
| Prediabetes | 5.7 – 6.4% |
| Diabetes | ≥6.5% |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.6 – 24.9 uIU/mL |
| Optimal/Functional Range | <5 – 8 uIU/mL |
| HOMA-IR (calculated) | <1.0 ideal |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| Glucose (fasting) | 65 – 99 mg/dL | 75 – 90 |
| ALT | 0 – 44 U/L | 10 – 26 |
| AST | 0 – 40 U/L | 10 – 26 |
| Albumin | 3.5 – 5.5 g/dL | 4.2 – 5.0 |
| BUN | 6 – 24 mg/dL | 10 – 16 |
| Creatinine | 0.76 – 1.27 mg/dL | 0.9 – 1.2 |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| Total Cholesterol | 100 – 199 mg/dL | 150 – 200 |
| LDL | 0 – 99 mg/dL | <100 |
| HDL | >39 mg/dL (men) | >50 |
| Triglycerides | 0 – 149 mg/dL | <100 |
| VLDL | 5 – 40 mg/dL | <20 |
| TG/HDL Ratio | — | <2.0 |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.40 – 4.50 uIU/mL |
| Optimal/Functional Range for weight loss | 0.5 – 2.5 uIU/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.82 – 1.77 ng/dL |
| Optimal/Functional Range | 1.1 – 1.5 ng/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range: Low risk | <1.0 mg/L |
| Quest Diagnostics Range: Average risk | 1.0 – 3.0 mg/L |
| Quest Diagnostics Range: High risk | >3.0 mg/L |
| Optimal/Functional Range | <0.55 mg/L |
| Measure | Range |
|---|---|
| Deficient | <20 ng/mL |
| Insufficient | 20 – 29 ng/mL |
| Quest Diagnostics Range | 30 – 100 ng/mL |
| Optimal/Functional Range | 50 – 80 ng/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 3.4 – 7.0 mg/dL (males) |
| Optimal/Functional Range | 3.5 – 5.5 mg/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 4 – 26 mcg/mL (males) |
| Low (metabolic risk) | <7 mcg/mL |
| Optimal/Functional Range | >10 mcg/mL |
$279 • 10 tests • 20+ biomarkers • Advanced heart disease risk assessment
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| Total Cholesterol | 100 – 199 mg/dL | 150 – 200 |
| LDL-C | 0 – 99 mg/dL | <100 (or <70 high risk) |
| HDL-C | >39 mg/dL (men) | >50 |
| Triglycerides | 0 – 149 mg/dL | <100 |
| VLDL | 5 – 40 mg/dL | <20 |
| TG/HDL Ratio | — | <2.0 |
| Measure | Range |
|---|---|
| Quest Diagnostics Range: Low risk | <1.0 mg/L |
| Quest Diagnostics Range: Average risk | 1.0 – 3.0 mg/L |
| Quest Diagnostics Range: High risk | >3.0 mg/L |
| Optimal/Functional Range | <0.55 mg/L |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | <130 mg/dL |
| Optimal (Quest) | <90 mg/dL |
| Optimal/Functional Range | <80 mg/dL |
| Aggressive (high risk) | <60 mg/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range: Low risk | <75 nmol/L (or <30 mg/dL) |
| Borderline | 75 – 125 nmol/L (30 – 50 mg/dL) |
| High risk | >125 nmol/L (>50 mg/dL) |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0 – 10.4 umol/L |
| Optimal/Functional Range | 5 – 7.2 umol/L |
| Elevated | >10.4 umol/L |
| Severely elevated | >15 umol/L |
| Measure | Range |
|---|---|
| Normal | <5.7% |
| Optimal | 4.8 – 5.3% |
| Prediabetes | 5.7 – 6.4% |
| Diabetes | ≥6.5% |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.6 – 24.9 uIU/mL |
| Optimal/Functional Range | <5 – 8 uIU/mL |
| HOMA-IR ideal | <1.0 |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 200 – 400 mg/dL |
| Optimal/Functional Range | 200 – 300 mg/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range: Low risk | <6.2 umol/L |
| Quest Diagnostics Range: Moderate risk | 6.2 – 9.9 umol/L |
| Quest Diagnostics Range: High risk | ≥10.0 umol/L |
| Biomarker | Quest Diagnostics Range | Optimal/Functional Range |
|---|---|---|
| LDL-P (particle number) | <1138 nmol/L (optimal) | <1000 nmol/L |
| Small LDL-P | <142 nmol/L (optimal) | As low as possible |
| LDL Size | >20.5 nm | >21.0 nm (Pattern A) |
| HDL-P (particle number) | — | >30.5 umol/L |
$149 • 6 tests • 8 biomarkers • Full thyroid function and autoimmune assessment
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.40 – 4.50 uIU/mL |
| Optimal/Functional Range | 0.5 – 2.5 uIU/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.82 – 1.77 ng/dL |
| Optimal/Functional Range | 1.1 – 1.5 ng/dL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 2.3 – 4.2 pg/mL |
| Optimal/Functional Range | 3.0 – 4.0 pg/mL |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 9.2 – 24.1 ng/dL |
| Optimal/Functional Range | 10 – 15 ng/dL |
| Free T3:rT3 ratio | >20 is optimal |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | <9 IU/mL |
| Optimal/Functional Range | <2 IU/mL (undetectable) |
| Measure | Range |
|---|---|
| Quest Diagnostics Range | 0.0 – 0.9 IU/mL |
| Optimal/Functional Range | Undetectable |
4 tests covering 8+ biomarkers that evaluate intestinal inflammation, celiac disease, fungal overgrowth, and systemic inflammation originating from the gut.
Calprotectin is a protein released by neutrophils (white blood cells) during intestinal inflammation. It is measured in stool and directly reflects the degree of immune activation within the gut lining.
It non-invasively differentiates inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS), potentially sparing patients from unnecessary colonoscopies.
| Category | Value (mcg/g) | Interpretation |
|---|---|---|
| Normal | <50 | No significant gut inflammation |
| Borderline | 50–120 | Mild inflammation; retest in 4–6 weeks |
| Elevated | >120 | IBD likely; GI referral recommended |
| Significantly Elevated | >250 | Active IBD flare |
Low or normal calprotectin is reassuring — it strongly suggests the absence of significant inflammatory bowel disease. Symptoms are more likely functional (IBS) in origin.
Causes: Crohn's disease, ulcerative colitis, NSAID use, GI infections, colorectal cancer, diverticulitis.
Symptoms: Chronic diarrhea, bloody stool, abdominal pain, unintended weight loss, fatigue.
A panel of antibodies that detects autoimmune reactivity to gluten. It includes tissue transglutaminase IgA (tTG-IgA), endomysial antibodies (EMA-IgA), deamidated gliadin peptide antibodies (DGP IgA/IgG), and total IgA. Approximately 83% of people with celiac disease remain undiagnosed.
To screen for celiac disease, which causes villous atrophy and malabsorption — the patient must be consuming gluten for accurate results.
| Marker | Negative | Positive | Notes |
|---|---|---|---|
| tTG-IgA | <4 U/mL | >10 U/mL | Primary screen; 4–10 weak positive |
| EMA-IgA | Negative | Positive | Confirmatory, ~100% specificity |
| DGP IgA | <20 U | ≥20 U | Useful in IgA-deficient patients |
| DGP IgG | <20 U | ≥20 U | Useful in IgA-deficient patients |
| Total IgA | 87–352 mg/dL | — | Low IgA causes false-negative tTG/EMA |
Negative antibodies with adequate IgA levels effectively rules out celiac disease. Low total IgA (<7 mg/dL) can produce false-negative tTG and EMA results — DGP IgG becomes the preferred marker.
Causes: Celiac disease (autoimmune reaction to gluten). tTG >10x upper limit is virtually diagnostic without biopsy per ESPGHAN guidelines.
Symptoms: Diarrhea, bloating, weight loss, iron-deficiency anemia, osteoporosis, dermatitis herpetiformis, neuropathy, fatigue, brain fog.
A panel measuring three classes of antibodies against Candida species. IgM indicates acute or recent infection, IgA reflects mucosal/GI involvement, and IgG suggests chronic or past exposure.
To evaluate for systemic or mucosal candida overgrowth, particularly in patients with unexplained GI symptoms, brain fog, and recurrent yeast issues.
| Antibody Class | Negative | Equivocal | Positive |
|---|---|---|---|
| IgM (Acute) | <1.0 | 1.0–1.4 | >1.4 |
| IgA (Mucosal/GI) | <1.0 | 1.0–1.4 | >1.4 |
| IgG (Chronic) | <1.0 | 1.0–1.4 | >1.4 |
Negative results suggest no significant immune response to Candida. Symptoms are likely attributable to other causes such as SIBO, food sensitivities, or dysbiosis.
Causes: Candida overgrowth from antibiotic use, high-sugar diet, immunosuppression, diabetes, chronic stress. Note: a positive IgG alone may reflect past exposure rather than active infection.
Symptoms: Bloating, brain fog, sugar cravings, fatigue, recurrent vaginal/oral thrush, skin rashes, joint pain.
High-sensitivity C-reactive protein is an acute-phase reactant produced by the liver in response to systemic inflammation. It is one of the most widely used biomarkers for chronic low-grade inflammation.
To assess systemic inflammation, which in the context of gut health may originate from intestinal permeability, dysbiosis, or food sensitivities.
| Category | Value (mg/L) | Interpretation |
|---|---|---|
| Optimal | <0.55 | Minimal systemic inflammation |
| Low Risk | <1.0 | Low cardiovascular / inflammatory risk |
| Moderate Risk | 1.0–3.0 | Moderate inflammation present |
| High Risk | >3.0 | Significant inflammation; investigate source |
| Acute Infection | >10.0 | Acute illness — retest when resolved |
Low hs-CRP indicates minimal systemic inflammation and lower cardiovascular risk. This is the desired outcome.
Causes: Gut inflammation, obesity (visceral fat), metabolic syndrome, autoimmune disease, chronic infection, periodontal disease, sleep apnea. The marker is non-specific.
Symptoms: Often asymptomatic until inflammation drives end-organ damage. May present as fatigue, joint stiffness, or worsened metabolic markers.
A focused 4-metal toxicology screen measuring the most clinically relevant environmental heavy metals that accumulate in the body and disrupt cellular function.
Arsenic is a naturally occurring metalloid found in soil and groundwater. Chronic low-level exposure — primarily through rice, drinking water, and pesticides — causes oxidative stress and DNA damage at the cellular level.
To identify chronic environmental arsenic exposure, which is linked to increased cardiovascular disease, diabetes, and cancer risk.
| Category | Value (mcg/L) | Interpretation |
|---|---|---|
| Normal | <23 | No significant exposure |
| Elevated | 23–50 | Above-average exposure; identify sources |
| High | >50 | Significant exposure; intervention needed |
Normal levels indicate no significant arsenic burden. No intervention needed.
Causes: Contaminated well water, high rice consumption (especially rice grown in Southern U.S.), pesticide exposure, pressure-treated wood, occupational exposure.
Symptoms: Fatigue, GI disturbances, peripheral neuropathy, skin changes (hyperpigmentation, keratoses), increased cancer risk (skin, lung, bladder), cardiovascular damage.
Cadmium is a toxic heavy metal that accumulates primarily in the kidneys and liver with a biological half-life of 10–30 years. It disrupts zinc-dependent enzymes and causes oxidative damage to tissues.
To detect chronic cadmium exposure, which causes progressive kidney damage, bone demineralization, and increases cancer risk.
| Category | Value (mcg/L) | Interpretation |
|---|---|---|
| Quest Diagnostics Range | 0–6.5 | Within reference range |
| Elevated | >6.5 | Significant exposure; investigate and intervene |
Normal cadmium indicates minimal toxic exposure. No specific intervention required.
Causes: Cigarette smoking (single largest source), contaminated food (leafy greens, shellfish, organ meats from contaminated soil), occupational/industrial exposure, some fertilizers.
Symptoms: Kidney damage (proteinuria, decreased GFR), bone loss/osteoporosis (itai-itai disease), lung damage, increased risk of kidney, lung, and prostate cancer.
Lead is a cumulative neurotoxin that is stored in bone and soft tissue. It inhibits enzymatic processes, disrupts calcium signaling, and damages the nervous system. There is no known safe level of lead exposure.
To detect lead exposure, which even at low levels is associated with cognitive decline, hypertension, kidney damage, and hormone disruption.
| Category | Value (mcg/dL) | Interpretation |
|---|---|---|
| Quest Diagnostics Range | <5.0 | Within reference range |
| Elevated | 5–44 | Above reference; source identification and intervention |
| Severe | ≥45 | Medical emergency; chelation required |
Levels below 3.5 mcg/dL are below the CDC reference value, though no level is considered truly safe. Minimal current exposure.
Causes: Old paint (pre-1978 homes), contaminated water (lead pipes/solder), imported ceramics/spices/cosmetics, contaminated soil near highways, occupational exposure (construction, battery manufacturing).
Symptoms: Fatigue, abdominal pain, cognitive impairment, memory loss, mood changes, hypertension, peripheral neuropathy, decreased libido, reduced sperm quality, anemia, kidney damage.
Mercury is a potent neurotoxin that exists in multiple forms: methylmercury (from fish), elemental mercury (from dental amalgams), and inorganic mercury (industrial). It crosses the blood-brain barrier and disrupts thyroid function, neurological signaling, and mitochondrial activity.
To identify mercury burden, which contributes to cognitive impairment, thyroid dysfunction, autoimmunity, and chronic fatigue.
| Category | Value (mcg/L) | Interpretation |
|---|---|---|
| Quest Diagnostics Range | 0–14.9 | Within reference range |
| Elevated | 15–50 | Above reference; reduce sources and intervene |
| Toxic | >50 | Mercury poisoning; urgent treatment |
Levels below 5 mcg/L suggest no significant mercury accumulation. Baseline dietary fish intake is safe.
Causes: High consumption of large predatory fish (tuna, swordfish, shark, king mackerel), dental amalgam fillings (chronic low-level vapor release), occupational exposure, environmental contamination.
Symptoms: Brain fog, memory impairment, tremors, peripheral neuropathy, thyroid dysfunction, fatigue, metallic taste, mood instability, immune dysregulation, kidney damage.
13 tests covering 20+ biomarkers that provide a complete picture of your vitamin, mineral, antioxidant, and fatty acid status — the foundational building blocks of cellular health.
Vitamin D is a fat-soluble secosteroid hormone synthesized in the skin from UVB exposure and obtained through diet. It regulates calcium metabolism, immune function, gene expression, and over 1,000 physiological processes.
To assess vitamin D status, as deficiency is linked to bone loss, immune dysfunction, depression, and increased mortality — affecting an estimated 42% of U.S. adults.
| Category | Value (ng/mL) | Interpretation |
|---|---|---|
| Deficient | <20 | Increased disease risk; supplementation required |
| Insufficient | 20–29 | Suboptimal; supplementation recommended |
| Quest Diagnostics Range | 30–100 | Within lab reference |
| Optimal | 50–80 | Functional medicine target |
| Potentially Toxic | >100 | Risk of hypercalcemia |
Causes: Insufficient sun exposure, dark skin pigmentation, obesity (vitamin D sequestered in fat), malabsorption, aging, northern latitude, sunscreen overuse.
Symptoms: Fatigue, depression, muscle weakness, bone pain, frequent infections, slow wound healing, hair loss, bone loss/osteoporosis.
Causes: Excessive supplementation (rarely from sun exposure). Symptoms: Hypercalcemia, nausea, kidney stones, calcification of soft tissues. Extremely rare below 150 ng/mL.
RBC magnesium measures intracellular magnesium stores — a far more accurate reflection of true magnesium status than serum magnesium. Magnesium is a cofactor in over 600 enzymatic reactions, including ATP production, DNA repair, and neurotransmitter synthesis.
To detect magnesium deficiency, which affects an estimated 80% of the population and contributes to anxiety, insomnia, muscle cramps, and cardiovascular risk.
| Category | Value (mg/dL) | Interpretation |
|---|---|---|
| Quest Diagnostics Range | 4.2–6.8 | Lab reference |
| Optimal | 6.0–6.8 | Upper quartile target |
| Suboptimal | <5.5 | Likely functionally deficient |
Causes: Soil depletion, processed food diet, stress (burns magnesium), alcohol, proton pump inhibitors, diabetes, aging.
Symptoms: Muscle cramps/twitching, insomnia, anxiety, heart palpitations, constipation, headaches/migraines, restless legs, high blood pressure.
Causes: Excessive supplementation, kidney failure (rare). Symptoms: Diarrhea, nausea, muscle weakness, very high levels can affect cardiac rhythm.
Vitamin B12 is a water-soluble vitamin essential for myelin synthesis (nerve sheath protection), red blood cell formation, DNA synthesis, and methylation. It is exclusively obtained from animal-source foods or supplements.
To detect B12 deficiency, which causes irreversible neurological damage if untreated and is common in vegans/vegetarians, older adults, and patients on metformin or PPIs.
| Category | Value (pg/mL) | Interpretation |
|---|---|---|
| Deficient | <232 | Deficiency confirmed; treat immediately |
| Quest Diagnostics Range | 232–1,245 | Lab reference |
| Optimal | 500–800 | Functional medicine target |
| Gray Zone | 200–400 | Possible functional deficiency; check MMA |
Causes: Vegan/vegetarian diet, pernicious anemia (autoimmune), gastric bypass, atrophic gastritis, metformin use, PPI use, aging (reduced intrinsic factor).
Symptoms: Peripheral neuropathy (tingling/numbness), fatigue, macrocytic anemia, cognitive decline, glossitis (swollen tongue), depression, balance problems.
Causes: Supplementation, liver disease, myeloproliferative disorders. Rarely harmful from supplementation alone. Unexplained very high levels warrant liver evaluation.
RBC folate measures tissue folate stores over the prior 3–4 months — more reliable than serum folate which fluctuates with recent intake. Folate is essential for DNA synthesis, methylation, and red blood cell production.
To assess long-term folate status, which is critical for cardiovascular health (homocysteine metabolism), mood regulation, and cellular repair.
| Category | Value (ng/mL) | Interpretation |
|---|---|---|
| Deficient | <280 | True deficiency |
| Quest Diagnostics Range | >280 | Lab reference |
| Optimal | 500–1,500 | Functional target |
Causes: Poor dietary intake, MTHFR gene variants (impaired folate metabolism), alcohol use, malabsorption, medications (methotrexate, phenytoin, sulfasalazine).
Symptoms: Macrocytic anemia, elevated homocysteine (cardiovascular risk), fatigue, depression, neural tube defects (in pregnancy), mouth sores.
Excessively high RBC folate is uncommon and typically results from supplementation. Very high unmetabolized folic acid (synthetic form) may mask B12 deficiency.
Ferritin is the primary iron storage protein. It reflects total body iron reserves and is also an acute-phase reactant, meaning it rises during inflammation, infection, and liver disease — which can mask underlying iron deficiency.
To evaluate iron stores, which are essential for oxygen transport, energy production, and thyroid function — and to screen for iron overload (hemochromatosis).
| Category | Value (ng/mL) | Interpretation |
|---|---|---|
| Iron Deficiency | <30 | Depleted iron stores |
| Quest Diagnostics Range | 30–400 | Lab reference |
| Optimal | 50–150 | Functional target |
| Elevated | >200 (women) / >300 (men) | Investigate: inflammation vs. overload |
| Overload Concern | >500 | Rule out hemochromatosis |
Causes: Inadequate dietary iron, heavy menstruation, GI bleeding, celiac disease, vegetarian/vegan diet, frequent blood donation, endurance exercise.
Symptoms: Fatigue, hair loss, restless legs, cold intolerance, brittle nails, shortness of breath, poor exercise tolerance, brain fog.
Causes: Hereditary hemochromatosis (HFE gene mutation), chronic inflammation, liver disease, metabolic syndrome, frequent alcohol use. Symptoms: Joint pain, fatigue, liver damage, skin bronzing, diabetes ("bronze diabetes"), heart failure.
The iron panel measures serum iron (circulating iron), TIBC (the blood's capacity to bind and transport iron), and transferrin saturation (the percentage of binding sites occupied by iron). Together they reveal iron kinetics — not just stores, but how iron is being used.
To distinguish between different types of iron disorders — deficiency, overload, and anemia of chronic disease each produce distinct patterns.
| Marker | Quest Diagnostics Range | Optimal |
|---|---|---|
| Serum Iron | 27–159 mcg/dL | 85–130 mcg/dL |
| TIBC | 250–370 mcg/dL | 275–350 mcg/dL |
| Transferrin Saturation | 15–55% | 25–45% |
Iron deficiency pattern: Low serum iron + high TIBC + low saturation. The body is iron-starved and producing more transferrin (transport protein) to try to capture whatever iron is available.
Iron overload pattern: High serum iron + low TIBC + high saturation (>50%). Seen in hemochromatosis. Anemia of chronic disease pattern: Low serum iron + low TIBC + normal/high ferritin — iron is "trapped" in storage by inflammation (hepcidin mechanism).
Retinol is the active, preformed version of vitamin A — a fat-soluble vitamin critical for vision (especially night vision), immune function, skin integrity, and gene expression. It is stored in the liver.
To assess vitamin A status, as both deficiency and toxicity have significant clinical consequences.
| Category | Value (mcg/dL) | Interpretation |
|---|---|---|
| Deficient | <38 | Below reference; supplement cautiously |
| Quest Diagnostics Range | 38–98 | Lab reference |
| Optimal | 50–80 | Functional target |
| Elevated/Toxic Risk | >100 | Possible hypervitaminosis A |
Causes: Poor dietary intake, fat malabsorption (celiac, IBD, pancreatic insufficiency), zinc deficiency (required for retinol transport), liver disease.
Symptoms: Night blindness, dry eyes (xerophthalmia), dry skin, frequent infections, poor wound healing.
Causes: Excessive supplementation with preformed vitamin A (retinol/retinyl palmitate), cod liver oil overuse, Accutane (isotretinoin). Symptoms: Liver toxicity (hepatotoxicity), headache, nausea, bone pain, birth defects (teratogenic).
Vitamin C is a water-soluble antioxidant essential for collagen synthesis, immune defense, iron absorption, and neurotransmitter production. Humans cannot synthesize it and must obtain it entirely from diet or supplements.
To assess vitamin C status, which is commonly suboptimal in smokers, the elderly, and those with limited fruit/vegetable intake.
| Category | Value (mg/dL) | Interpretation |
|---|---|---|
| Deficient (Scurvy Risk) | <0.4 | Severe deficiency |
| Quest Diagnostics Range | 0.4–2.0 | Lab reference |
| Optimal | 1.0–2.0 | Functional target |
Causes: Smoking (depletes vitamin C — smokers need 35mg more/day), poor diet, alcoholism, malabsorption, high oxidative stress states.
Symptoms: Poor wound healing, easy bruising, bleeding gums, weak immunity, dry/rough skin, fatigue, joint pain. Severe: scurvy (connective tissue breakdown).
Vitamin C is water-soluble and excess is excreted renally. Very high doses (>2,000mg/day) may cause GI distress, diarrhea, or increase kidney stone risk in susceptible individuals.
Copper is a trace mineral essential for iron metabolism, connective tissue formation, neurotransmitter synthesis, and antioxidant defense (via superoxide dismutase). It exists in a critical balance with zinc — the copper-to-zinc ratio is often more informative than either value alone.
To evaluate copper status and the copper-zinc ratio, as imbalances contribute to anemia, neuropathy, inflammation, and mood disorders.
| Marker | Quest Diagnostics Range | Optimal |
|---|---|---|
| Serum Copper (males) | 72–166 mcg/dL | 70–110 mcg/dL |
| Copper:Zinc Ratio | — | 0.7–1.0 (ideal) |
Causes: Excess zinc supplementation (most common cause — zinc competes with copper), gastric bypass, Menkes disease (rare genetic). Symptoms: Anemia unresponsive to iron, neutropenia, peripheral neuropathy (mimics B12 deficiency), osteoporosis.
Causes: Chronic inflammation, estrogen therapy/oral contraceptives, liver disease, Wilson disease (genetic copper overload). Symptoms: Oxidative stress, mood instability, anxiety, liver damage, Kayser-Fleischer rings (Wilson disease).
Iodine is a trace element required for thyroid hormone synthesis (T3 and T4). The thyroid gland concentrates iodine at 20–40 times its serum level. Adequate iodine is essential for metabolic rate, neurodevelopment, and reproductive health.
To assess iodine adequacy, as both deficiency and excess impair thyroid function — and many people unknowingly consume too little or too much.
| Category | Value (mcg/L) | Interpretation |
|---|---|---|
| Deficient | <52 | Increased risk of hypothyroidism/goiter |
| Quest Diagnostics Range | 52–109 | Within reference range |
| Excessive | >109 | Increased thyroid autoantibody risk |
Causes: Non-iodized salt use, dairy-free/seafood-free diets, soil depletion, displacement by bromide/fluoride/chlorine. Symptoms: Goiter, hypothyroidism, fatigue, weight gain, cold intolerance, cognitive impairment, menstrual irregularities.
Causes: Excessive supplementation (kelp/seaweed), iodine-containing contrast dye, amiodarone. Paradoxically can cause either hyperthyroidism (Jod-Basedow) or hypothyroidism (Wolff-Chaikoff effect). Levels >130 mcg/L associated with 5.79× increased risk of thyroid autoantibodies.
Coenzyme Q10 is a fat-soluble antioxidant found in every cell's mitochondria, where it plays a central role in the electron transport chain — the final step of cellular energy (ATP) production. Production declines significantly with age.
To assess mitochondrial energy capacity, particularly in patients on statins (which deplete CoQ10), those with fatigue, cardiovascular disease, or age-related decline.
| Category | Value (mg/L) | Interpretation |
|---|---|---|
| Deficient | <0.44 | Clinically significant depletion |
| Quest Diagnostics Range | 0.44–1.64 | Lab reference |
| Optimal | 1.0–3.0 | Functional medicine target |
Causes: Statin medications (block the same pathway that produces CoQ10), aging (production drops ~50% by age 50), heart failure, fibromyalgia, mitochondrial dysfunction, chronic disease.
Symptoms: Statin-induced myopathy (muscle pain/weakness), fatigue, exercise intolerance, brain fog, gum disease, weakened immune function.
High CoQ10 from supplementation is generally safe and not associated with toxicity. No upper limit has been established.
This test measures omega-3 fatty acids (EPA and DHA in red blood cell membranes — the "Omega-3 Index") and the ratio of pro-inflammatory omega-6 to anti-inflammatory omega-3 fats. The Omega-3 Index reflects the prior 3 months of intake.
To assess essential fatty acid balance, which profoundly influences cardiovascular risk, brain health, inflammation, and cell membrane integrity.
| Marker | Suboptimal | Optimal |
|---|---|---|
| Omega-3 Index (RBC EPA+DHA) | <3.5% (high risk), 3.5–5.3% (intermediate) | ≥5.4% (desirable) |
| Omega-6:Omega-3 Ratio | >10:1 (pro-inflammatory) | <4:1 (ideal) |
The average Western diet produces an omega-6:3 ratio of 15–20:1.
Causes: Low fish/seafood intake, high seed oil consumption, standard American diet. Symptoms: Dry skin and eyes, joint stiffness, depression/anxiety, poor memory, increased cardiovascular risk, systemic inflammation.
Causes: Excessive consumption of seed/vegetable oils (soybean, corn, sunflower, canola), fried foods, processed snacks. Promotes a pro-inflammatory cellular environment.
Glutathione is the body's "master antioxidant" — a tripeptide (glutamate, cysteine, glycine) produced in every cell. It neutralizes free radicals, regenerates other antioxidants (vitamins C and E), supports Phase II liver detoxification, and modulates immune function.
To assess the body's antioxidant reserve and detoxification capacity, which declines with age, chronic illness, and toxic exposures.
| Category | Value (umol/L) | Interpretation |
|---|---|---|
| Low | <795 | Depleted; oxidative stress likely |
| Quest Diagnostics Range | 795–1,285 | Lab reference |
| Optimal | Upper quartile of range | Robust antioxidant capacity |
Causes: Chronic illness, heavy metal/toxin burden, MTHFR gene variants (impaired methylation feeding glutathione production), aging, acetaminophen overuse, alcohol, poor protein intake, oxidative stress.
Symptoms: Fatigue, brain fog, frequent illness, poor detoxification, chemical sensitivities, accelerated aging, increased susceptibility to chronic disease.
High glutathione is desirable and indicates strong antioxidant defense. Not associated with toxicity.
8 tests covering 15+ biomarkers that provide a comprehensive evaluation of androgen status, estrogen balance, growth factors, thyroid function, and prostate health.
Total testosterone measures all circulating testosterone — both bound (to SHBG and albumin) and free. It is the primary male sex hormone, responsible for muscle mass, bone density, red blood cell production, libido, mood, and cognitive function.
To screen for hypogonadism (low testosterone), which affects an estimated 20–40% of men over 45 and is a leading cause of fatigue, sexual dysfunction, and metabolic decline.
| Category | Value (ng/dL) | Interpretation |
|---|---|---|
| Low (Hypogonadism) | <300 | AUA/Endocrine Society threshold for treatment |
| Quest Diagnostics Range | 250–1,100 | Lab reference (age-inclusive) |
| Optimal | 500–900 | Functional target for symptom resolution |
Causes: Aging (1–2% decline/year after 30), obesity (aromatase converts T to estrogen), opioids, sleep apnea, pituitary disorders, chronic stress (cortisol suppresses GnRH), diabetes, varicocele.
Symptoms: Fatigue, low libido, erectile dysfunction, depression, brain fog, muscle loss, increased body fat, irritability, decreased motivation, osteoporosis.
Causes: Exogenous testosterone use, anabolic steroid abuse, adrenal tumors, congenital adrenal hyperplasia. Symptoms: Acne, hair loss, aggression, polycythemia (elevated hematocrit), sleep apnea worsening.
Free testosterone is the unbound, biologically active fraction of total testosterone — only 1–3% circulates freely. It is the form that can enter cells and activate androgen receptors, making it arguably more clinically relevant than total testosterone.
Because total testosterone can appear normal while free testosterone is low (due to elevated SHBG), free T reveals the true amount of active hormone available to tissues.
| Category | Value (pg/mL) | Interpretation |
|---|---|---|
| Low | <35 | Functionally deficient |
| Quest Diagnostics Range | 35–155 | Lab reference |
| Optimal | 100–200 | Functional target |
Causes: Elevated SHBG (aging, liver disease, hyperthyroidism, low-calorie diets), primary or secondary hypogonadism. Symptoms identical to low total T: fatigue, low libido, ED, mood changes, muscle loss.
Causes: TRT/anabolic steroid use, low SHBG. Symptoms: Acne, oily skin, hair thinning, polycythemia, potential prostate stimulation.
SHBG is a glycoprotein produced by the liver that binds testosterone and estradiol, regulating how much free (active) hormone is available to tissues. It acts as a hormonal thermostat — too high or too low disrupts the balance.
To understand why total testosterone may not match symptoms — SHBG is the key modifier that determines free hormone availability.
| Category | Value (nmol/L) | Interpretation |
|---|---|---|
| Low | <20 | More free T but also more free estrogen; metabolic concern |
| Quest Diagnostics Range | 10–50 | Lab reference |
| Optimal | 20–40 | Balanced free hormone availability |
| High | >50 | Binds too much T; symptoms of low T despite normal total |
Causes: Insulin resistance/metabolic syndrome, obesity, type 2 diabetes, hypothyroidism, anabolic steroid use, high-dose testosterone. Clinical significance: More free T and free estradiol — may drive estrogenic symptoms (gynecomastia, water retention).
Causes: Aging, hyperthyroidism, liver disease, HIV, low-calorie diets, oral estrogen, anticonvulsants. Clinical significance: Total T looks normal on paper but free T is actually low — the patient is functionally hypogonadal.
Estradiol (E2) is the primary estrogen in men, produced by aromatase conversion of testosterone in fat tissue, brain, and bone. Men need estradiol for bone health, brain function, and cardiovascular protection — but excess causes feminizing side effects.
To monitor estrogen balance, especially in men on TRT (testosterone is a substrate for aromatase), obese men, and those with gynecomastia or water retention.
| Category | Value (pg/mL) | Interpretation |
|---|---|---|
| Low | <15 | Joint pain, bone loss, low mood |
| Quest Diagnostics Range | 8–35 | Lab reference (sensitive assay for men) |
| Optimal | 20–30 | Balanced target |
| High | >35 | Estrogenic symptoms likely |
Causes: Over-aggressive aromatase inhibitor use, very low body fat, low testosterone substrate. Symptoms: Joint pain/stiffness, bone loss, depression, decreased libido (paradoxically), fatigue, dry skin.
Causes: Obesity (increased aromatase in adipose tissue), TRT (more substrate to convert), liver dysfunction, alcohol use. Symptoms: Gynecomastia (breast tissue growth), water retention/bloating, emotional lability, erectile dysfunction, reduced libido.
DHEA-S is the sulfated form of DHEA, the most abundant circulating steroid hormone. Produced primarily by the adrenal glands, it serves as a precursor to both testosterone and estrogen. DHEA-S peaks in the mid-20s and declines steadily with age.
To evaluate adrenal androgen production, assess "adrenal reserve," and identify premature hormonal aging or adrenal dysfunction.
| Age Group | Quest Diagnostics Range (mcg/dL) | Interpretation |
|---|---|---|
| 20–29 | 280–640 | Peak adrenal output |
| 30–39 | 120–520 | Early decline phase |
| 40–49 | 95–530 | Mid-life range |
| 50–59 | 70–310 | Significant decline expected |
| 60–69 | 42–290 | Age-appropriate range |
| Optimal | Age-matched upper quartile | Youthful adrenal output |
Causes: Aging (natural decline), chronic stress/HPA axis dysfunction, long-term corticosteroid use, adrenal insufficiency. Symptoms: Fatigue, low libido, reduced muscle mass, depressed mood, dry skin, weakened immunity.
Causes: Adrenal tumors, congenital adrenal hyperplasia, PCOS (in women), exogenous DHEA supplementation. Symptoms: Acne, oily skin, hair loss, aggression.
DHT is the most potent androgen in the male body — 3 to 5 times stronger than testosterone at the androgen receptor. It is produced from testosterone by the enzyme 5-alpha reductase, primarily in the prostate, skin, hair follicles, and liver.
To assess androgenic potency, especially in men with hair loss, BPH symptoms, or those on TRT/5-alpha reductase inhibitors.
| Category | Value (ng/dL) | Interpretation |
|---|---|---|
| Low | <12 | Reduced androgenic activity |
| Quest Diagnostics Range | 12–65 | Lab reference (adult males) |
| Optimal | 30–50 | Balanced androgenic function |
| High | >65 | Androgenic excess — hair loss/prostate concern |
Causes: 5-alpha reductase inhibitors (finasteride, dutasteride), hypogonadism, aging. Symptoms: Low libido, erectile dysfunction, reduced facial/body hair, metabolic syndrome, delayed wound healing.
Causes: High 5-alpha reductase activity (genetic), TRT (especially with cream/topical), anabolic steroid use. Symptoms: Androgenic alopecia (male pattern baldness), benign prostatic hyperplasia (BPH), acne, oily skin, prostate growth.
IGF-1 is a peptide hormone produced primarily in the liver in response to growth hormone (GH). It mediates most of GH's anabolic effects — muscle growth, bone density, tissue repair, and cellular regeneration. It serves as a reliable proxy for overall growth hormone status.
Because growth hormone itself is pulsatile and difficult to measure directly, IGF-1 provides a stable, reliable indicator of GH axis activity.
| Age Group | Quest Diagnostics Range (ng/mL) | Interpretation |
|---|---|---|
| 20–29 | 115–355 | Peak GH axis output |
| 30–39 | 96–228 | Early decline |
| 40–49 | 83–220 | Mid-life range |
| 50–59 | 66–186 | Age-related decline |
| 60–69 | 62–176 | Expected lower range |
| 70+ | 50–166 | Age-appropriate range |
Ranges are age-dependent — always interpret against age-matched reference. Values above or below range warrant clinical evaluation.
Causes: GH deficiency, poor sleep, caloric restriction, liver disease, aging, chronic illness, hypothyroidism. Symptoms: Fatigue, muscle wasting, decreased bone density, increased body fat, poor recovery, thin skin, impaired wound healing.
Causes: Acromegaly (pituitary adenoma), exogenous GH/peptide use, puberty. Concerns: Very high IGF-1 levels are associated with increased risk of certain cancers (prostate, colorectal, breast).
PSA is a serine protease enzyme produced exclusively by prostate epithelial cells. It liquefies semen and is present in small amounts in the blood. Elevations can indicate prostate cancer, BPH, prostatitis, or recent prostate manipulation.
To screen for prostate pathology and establish a baseline — especially important for men on testosterone replacement therapy, which stimulates prostate tissue.
| Age Group | Quest Diagnostics Range (ng/mL) | Interpretation |
|---|---|---|
| 40–49 | 0–2.5 | Age-adjusted normal |
| 50–59 | 0–3.5 | Age-adjusted normal |
| 60–69 | 0–4.5 | Age-adjusted normal |
| 70–79 | 0–6.5 | Age-adjusted normal |
| Gray Zone | Above age-based cutoff to 10.0 | 25% chance of cancer; further workup |
| Elevated | >10.0 | >50% chance of cancer; urology referral urgent |
Low PSA is reassuring and indicates low prostate cancer risk. Very low PSA may also be seen with 5-alpha reductase inhibitor use (finasteride/dutasteride reduce PSA by ~50%).
Causes: Prostate cancer, BPH, prostatitis, urinary tract infection, recent ejaculation (wait 48 hrs), cycling, digital rectal exam. Key metric on TRT: A PSA rise >1.4 ng/mL over baseline warrants urology referral.
Prolactin is a pituitary hormone primarily known for lactation in women, but in men it plays a role in reproductive function, immune regulation, and dopamine feedback. Elevated prolactin in men directly suppresses GnRH, leading to reduced testosterone production.
To identify hyperprolactinemia as a cause of low testosterone, sexual dysfunction, or infertility — and to screen for pituitary prolactinoma.
| Category | Value (ng/mL) | Interpretation |
|---|---|---|
| Quest Diagnostics Range | 2.0–18.0 | Healthy range for men |
| Mildly Elevated | 18–50 | Medication-related or stress; recheck |
| Significantly Elevated | 50–200 | Microprolactinoma possible; pituitary MRI |
| Markedly Elevated | >200 | Macroprolactinoma likely; urgent imaging |
Low prolactin is generally benign and often favorable in men. May be seen with dopamine agonist therapy or pituitary damage (rare).
Causes: Prolactinoma (pituitary tumor), medications (antipsychotics, SSRIs, metoclopramide, opioids), hypothyroidism, kidney failure, chest wall irritation, marijuana use, stress.
Symptoms: Erectile dysfunction, low libido, infertility, gynecomastia, galactorrhea, headaches, visual field changes (if prolactinoma compresses optic chiasm).
TSH is a pituitary hormone that signals the thyroid gland to produce T4 and T3. It operates on a negative feedback loop — when thyroid hormone is low, TSH rises to stimulate production; when thyroid hormone is adequate, TSH decreases.
As the primary thyroid screening marker — thyroid dysfunction profoundly affects testosterone production, metabolism, energy, mood, and sexual function in men.
| Category | Value (uIU/mL) | Interpretation |
|---|---|---|
| Hyperthyroid | <0.40 | Overactive thyroid or excessive medication |
| Optimal | 0.5–2.5 | Functional medicine target |
| Quest Diagnostics Range | 0.40–4.50 | Lab reference |
| Subclinical Hypothyroid | 2.5–4.50 | Early thyroid sluggishness; evaluate further |
| Hypothyroid | >4.50 | Overt hypothyroidism likely |
Causes: Graves' disease, thyroiditis, excessive thyroid medication, pituitary insufficiency. Symptoms: Weight loss, anxiety, tremor, heat intolerance, palpitations, insomnia, diarrhea, increased SHBG (lowering free T).
Causes: Hashimoto's thyroiditis, iodine deficiency, lithium, amiodarone, pituitary adenoma (rare). Symptoms: Fatigue, weight gain, cold intolerance, constipation, depression, dry skin, hair loss, low testosterone, erectile dysfunction.
Free T4 is the unbound, available form of the thyroid's primary hormone output. T4 is a prohormone — it must be converted to the active form T3 by deiodinase enzymes in peripheral tissues (liver, kidneys, gut). Free T4 represents thyroid gland output before peripheral conversion.
To evaluate actual thyroid hormone production alongside TSH, providing a more complete picture of thyroid function than TSH alone.
| Category | Value (ng/dL) | Interpretation |
|---|---|---|
| Low | <0.82 | Hypothyroidism |
| Quest Diagnostics Range | 0.82–1.77 | Lab reference |
| Optimal | 1.1–1.5 | Functional target |
| High | >1.77 | Hyperthyroidism or overmedication |
Causes: Hashimoto's thyroiditis, iodine deficiency, pituitary failure (central hypothyroidism — TSH may be low/normal despite low T4). Symptoms: Identical to hypothyroidism — fatigue, weight gain, cold intolerance, depression, brain fog.
Causes: Graves' disease, toxic nodular goiter, thyroiditis (transient release), excessive thyroid medication. Symptoms: Anxiety, weight loss, heat intolerance, tremor, rapid heart rate.
5 tests covering 35+ biomarkers — the foundational wellness panel that screens metabolic function, blood counts, cardiovascular lipids, and thyroid/hormonal status in a single draw.
The CMP is a panel of 16 blood tests that provides a snapshot of your metabolic health — blood sugar regulation, kidney function, liver function, electrolyte balance, and protein status. It is the most commonly ordered blood panel in medicine.
To screen for diabetes, kidney disease, liver disease, and electrolyte imbalances — conditions that are often asymptomatic until advanced.
| Marker | Quest Diagnostics Range | Optimal |
|---|---|---|
| Glucose (fasting) | 65–99 mg/dL | 75–90 mg/dL |
| BUN | 6–24 mg/dL | 10–16 mg/dL |
| Creatinine | 0.76–1.27 mg/dL | 0.9–1.2 mg/dL |
| eGFR | >60 mL/min | >90 mL/min |
| ALT | 0–44 U/L | 10–26 U/L |
| AST | 0–40 U/L | 10–26 U/L |
| ALP | 44–147 U/L | 50–100 U/L |
| Total Bilirubin | 0.0–1.2 mg/dL | 0.3–0.8 mg/dL |
| Albumin | 3.5–5.5 g/dL | 4.2–5.0 g/dL |
| Total Protein | 6.0–8.5 g/dL | 6.5–7.5 g/dL |
| Sodium | 134–144 mEq/L | 138–142 mEq/L |
| Potassium | 3.5–5.2 mEq/L | 4.0–4.5 mEq/L |
| Chloride | 96–106 mEq/L | 100–104 mEq/L |
| CO2 (Bicarb) | 20–29 mEq/L | 24–27 mEq/L |
| Calcium | 8.7–10.2 mg/dL | 9.2–10.0 mg/dL |
| Globulin | 1.5–4.5 g/dL | 2.0–3.5 g/dL |
| A/G Ratio | 1.2–2.2 | 1.5–2.0 |
The complete blood count with differential measures red blood cells (oxygen transport), white blood cells broken down by type (immune function), and platelets (clotting). It is the most fundamental blood test for evaluating overall health, anemia, infection, and blood disorders.
To screen for anemia, infection, immune status, and clotting function — and critically, to monitor hematocrit and hemoglobin in men on TRT (polycythemia risk).
| Marker | Quest Diagnostics Range | Optimal |
|---|---|---|
| WBC | 3.4–10.8 x10E3/uL | 5.0–7.0 x10E3/uL |
| RBC | 4.14–5.80 M/uL | 4.5–5.5 M/uL |
| Hemoglobin (Hgb) | 12.6–17.7 g/dL | 14.5–16.5 g/dL |
| Hematocrit (Hct) | 37.5–51.0% | 42–48% |
| MCV | 79–97 fL | 85–92 fL |
| MCH | 27–33 pg | 28–32 pg |
| MCHC | 31.5–35.7 g/dL | 33–35 g/dL |
| RDW | 11.5–14.5% | <13% |
| Platelets | 150–379 x10E3/uL | 200–300 x10E3/uL |
| Neutrophils | 40–60% | — |
| Lymphocytes | 20–40% | — |
| Monocytes | 2–8% | — |
| Eosinophils | 1–4% | — |
| Basophils | 0.5–1% | — |
The lipid panel measures cholesterol fractions and triglycerides — the primary blood fats that determine cardiovascular disease risk. It includes total cholesterol, LDL ("bad"), HDL ("good"), and triglycerides.
To assess cardiovascular risk — heart disease remains the #1 cause of death, and lipid patterns are among the strongest modifiable risk factors.
| Marker | Quest Diagnostics Range | Optimal |
|---|---|---|
| Total Cholesterol | 100–199 mg/dL | 160–200 mg/dL |
| LDL-C | 0–99 mg/dL | <100 mg/dL (lower if high CVD risk) |
| HDL-C | >39 mg/dL | >50 mg/dL (higher is protective) |
| Triglycerides | 0–149 mg/dL | <100 mg/dL |
| VLDL | 5–40 mg/dL | 5–30 mg/dL |
| TG/HDL Ratio | — | <2.0 (insulin sensitivity proxy) |
TSH is a pituitary hormone that regulates thyroid function via a negative feedback loop. It is the single most sensitive screening test for thyroid dysfunction — abnormalities appear in TSH before thyroid hormones themselves become overtly abnormal.
As the primary thyroid screen in this baseline panel — undiagnosed thyroid disease affects ~12% of Americans and mimics many common complaints (fatigue, weight gain, depression).
| Category | Value (uIU/mL) | Interpretation |
|---|---|---|
| Hyperthyroid | <0.40 | Suppressed TSH — overactive thyroid |
| Optimal | 0.5–2.5 | Functional medicine sweet spot |
| Quest Diagnostics Range | 0.40–4.50 | Lab reference |
| Subclinical Hypothyroid | 2.5–4.50 | Evaluate with Free T4 and symptoms |
| Overt Hypothyroid | >4.50 | Treatment indicated |
Causes: Graves' disease, thyroid nodule, thyroiditis, excess thyroid medication. Symptoms: Weight loss, anxiety, tremor, heat intolerance, insomnia, palpitations, diarrhea.
Causes: Hashimoto's thyroiditis (most common), iodine deficiency, medications (lithium, amiodarone). Symptoms: Fatigue, weight gain, cold intolerance, constipation, dry skin, depression, hair loss, brain fog.
Free T4 is the unbound form of thyroxine — the thyroid's primary output. It must be converted to the active form T3 by deiodinase enzymes. Measuring Free T4 alongside TSH confirms whether the thyroid gland itself is producing adequate hormone.
To confirm thyroid gland function when TSH is abnormal and to differentiate primary thyroid disease from pituitary (central) causes.
| Category | Value (ng/dL) | Interpretation |
|---|---|---|
| Low (Hypothyroid) | <0.82 | Insufficient thyroid output |
| Quest Diagnostics Range | 0.82–1.77 | Lab reference |
| Optimal | 1.1–1.5 | Mid-to-upper range target |
| High (Hyperthyroid) | >1.77 | Excess thyroid output |
With high TSH: Primary hypothyroidism (Hashimoto's, iodine deficiency). With low/normal TSH: Central hypothyroidism (pituitary problem) — less common but important to recognize.
With low TSH: Hyperthyroidism (Graves', toxic nodule). With normal/high TSH: TSH-secreting pituitary adenoma (very rare), thyroid hormone resistance.
Total testosterone measures all circulating testosterone — the primary male sex hormone governing muscle mass, bone density, mood, energy, libido, and metabolic health. It is included in this basic panel as a foundational screen for hormonal health in men.
To screen for hypogonadism (low T), which is increasingly prevalent and underlies many symptoms that patients attribute to "just getting older."
| Category | Value (ng/dL) | Interpretation |
|---|---|---|
| Low (Hypogonadism) | <300 | AUA/Endocrine Society diagnostic threshold |
| Quest Diagnostics Range | 250–1,100 | Lab reference |
| Optimal | 500–900 | Target for symptom resolution |
Causes: Aging, obesity, sleep deprivation, chronic stress, diabetes, opioid use, pituitary disorders, varicocele, Klinefelter syndrome.
Symptoms: Fatigue, low libido, erectile dysfunction, depression, muscle loss, increased body fat, decreased motivation, poor concentration, osteoporosis.
Causes: Exogenous testosterone/anabolic steroids, adrenal tumors. Symptoms: Acne, aggression, hair loss, polycythemia, sleep apnea worsening.
© 2026, TestosteroneShots.com PC
text (323)-283-9219
638 1/2 N Robertson Blvd, West Hollywood, CA 90069
The information and products provided on this website are for informational and wellness purposes only and are not intended to diagnose, treat, cure, or prevent any disease. All medical treatments are subject to evaluation and approval by a licensed healthcare provider through a telemedicine consultation. Individual results may vary, and the use of any product carries potential risks and side effects that should be discussed with a qualified medical professional. These products are not approved by the FDA unless explicitly stated, and misuse or unauthorized sharing is strictly prohibited. By using this site or purchasing any service, you agree to our Terms of Service, Telehealth Consent, and Privacy Policy. We prioritize your privacy and comply with HIPAA regulations for protected health information. Services provided by licensed physicians/nurse practitioners in states served, e.g., CA, FL, and others, via telemedicine. Check your state's telemedicine laws. Must Be 18+ or Older to Qualify For Treatment.